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11. INTRODUCTION
Symptoms of the spirochetal infecti-
on currently known as Lyme borre-
liosis (LB) have been familiar to phy-
sicians in Europe for more than 100
years. The discovery of the causati-
ve organism, Borrelia burgdorferi (B.
burgdorferi), by William Burgdorfer
(Figure 1.) and his associates in the
United States in 1981 elicited active
scientific work all around the nort-
hern hemisphere. LB is by far the
most common tick-borne infection in
the United States and Europe.
Of the subspecies thus far recogni-
zed as belonging to the B. burgdorferi
sensu lato complex, only three are
unambiguously pathogenic for hu-
mans. B. burgdorferi sensu stricto ap-
pear in North America and Europe,
whereas, in Europe, the subspecies
B. afzelii and B. garinii also cause LB.
The vector of the LB is usually an
infected tick, and in Europe it is pri-
marily the sheep tick Ixodes ricinus (I.
ricinus). The enzootic cycle is main-
tained by a broad spectrum of reser-
voir animals, the major ones for B.
burgdorferi being small and medium
sized mammals.
The clinical spectrum of LB is also
broad. The initial symptom, and
most common clinical finding and
hallmark of the disease, is an expan-
ding rash, erythema migrans (EM).
In this early stage the disease is usu-
ally easily treatable with antimicro-
bial therapy. Without treatment some
patients develop disseminated infec-
tion with many kinds of symptoms.
Even in the early clinical studies neu-
rootological symptoms were re-
ported for patients with LB. Cranial
nerve neuropathies are common
manifestations of neuroborreliosis in
both Europe and North America. The
facial nerve is the most commonly
Figure 1. Dr. William Burgdorfer disco-
vered the causative agent of Lyme bor-
reliosis in 1981.
2affected cranial nerve, but the dise-
ase can also affect other cranial ner-
ves, including the vestibulocochlear
nerve.
The cornerstone in the diagnostics of
LB is the clinical picture presented by
the patient. Laboratory tests can pro-
vide valuable information especial-
ly for the diagnosis of cases with
ambiguous symptoms and signs. If
pathognomonic EM is present, the
diagnosis can be made without labo-
ratory tests. Laboratory tests include
the detection of B. burgdorferi in eit-
her body fluids or tissues and the
assessment of antibodies to the spi-
rochete in serum or cerebrospinal
fluid (CSF).
The significance of B. burgdorferi cul-
tivation is limited as a diagnostic
tool, because it is rarely successful
from clinical specimens. The deter-
mination of DNA from B. burgdorferi
by polymerase chain reaction (PCR)
is gaining in use in the diagnosis of
LB. Detection of specific antibodies
against B. burgdorferi by enzyme-lin-
ked immunosorbent assay (ELISA) is
the most commonly used method to
screen patients for LB. ELISA can,
however, provide false positive re-
sults because of cross-reactions, and
a positive result in ELISA should be
confirmed by Western blotting. Un-
fortunately, Western blotting lacks
universally, or even locally, accepted
interpretation criteria.
In this study, the prevalence of LB
was evaluated for patients with fa-
cial nerve paralysis (FP), sudden sen-
sorineural hearing loss (SHL) and
vertigo. The infestation rate of ticks
with B. burgdorferi in the patient en-
rollment area was assessed by dark
field microscopy (DFM), PCR and
cultivation. The epidemiology of LB,
patients´ signs and symptoms of LB
and the recovery of neurootological
patients from LB, were also studied.
32. REVIEW OF THE LITERATURE
2.1. History of Lyme borreliosis
In 1883, the German Alfred Buch-
wald described a case of long-lasting
“diffuse idiopathic skin atrophy”
(Buchwald 1883). More than 20 case
reports of similar observations were
published during the next 20 years,
until Herxheimer and Hartman, in
1902, introduced the term acroder-
matitis chronica atrophicans (ACA)
for this late manifestation of LB
(Herxheimer et al. 1902). The expan-
ding rash around the site of a tick bite
was first described in Sweden in 1909
(Afzelius 1910). The symptom was
then called erythema chronicum mi-
grans, nowadays known as erythe-
ma migrans (EM). The association
between EM after a tick bite and ra-
diculoneuritis with meningitis was
first reported in France in 1922 (Ga-
rin et al. 1922). Subsequent publica-
tions reported a patient with menin-
goencephalitis after EM (Hellerström
1930) and 15 patients with “a chro-
nic lymphocytic meningitis with ce-
rebral symptoms” (Bannwarth 1941).
Already at that time Afzelius specu-
lated that EM could be infective and
produced by either a virus trans-
mitted by ticks or a toxic agent con-
taminating the ticks. In their conclu-
sion Garin and Bujadoux stated that
“a virus (probably a spirochete)“
may be the etiologic factor of the neu-
rologic symptoms appearing after a
tick bite (Garin et al. 1922). In 1923
Lipschütz, a dermatologist from
Vienna, stated (Lipschütz 1923) that
“...attention should be directed to-
wards microscopic/bacteriologic in-
vestigations of intestinal tract and
salivary gland secretions of the tick.“
- Nobody followed his proposal.
The suspicion of an infectious agent
behind the symptoms often led to
successful attempts to treat patients
with antimicrobial medication alrea-
dy several decades before the bacte-
rial etiology was discovered (Bianchi
1950; Thyresson 1950; Hollström
1951; Hellerström 1951; Weber 1974).
The infectious nature of EM was de-
monstrated with volunteers used to
transmit the disease from one person
to the other (Binder et al. 1955; Sonck
1965).
The modern era in the history of LB
began in the community of Lyme,
Connecticut in the United States at
the request of two concerned mot-
hers, Mrs. Polly Murray and Mrs.
Judith Mensch (Burgdorfer 1993).
One of the mothers was suffering
4from multisystem disease, which had
affected the children of both mothers
and also some members of neighbo-
ring families. The systematic study
of these patients (Steere et al. 1977;
Steere 1989) led to the discovery of
the causative agent (Burgdorfer et al.
1982) of this multisystem spiroche-
tal disease, then called Lyme disease
but later preferentially referred to as
Lyme borreliosis.
2.2. Characteristics of Borrelia
spirochetes
Order Spirochaetales
The causative agent of LB, B. burg-
dorferi, belongs to the order Spirochae-
tales. Another well-known human
pathogen of this order is Treponema
pallidum, the causative agent of
syphilis. Other members of the Bor-
relia genus, causing tick-borne and
louse-born relapsing fever, also have
a zoonotic cycle.
B. burgdorferi sensu lato
The Swiss-American scientist Wil-
liam Burgdorfer, along with his as-
sociates isolated B. burgdorferi from
Ixodes dammini ticks collected from
Shelter Island in New York (Burgdor-
fer et al. 1982). Genetic studies on the
DNA of B. burgdorferi sensu lato have
shown considerable heterogeneity
between different strains, and thus
far nine different species of the B.
burgdorferi sensu lato complex, inclu-
ding B. burgdorferii sensu stricto, B.
garinii, B. afzelii, B. lusitaniae, B. valai-
siana, B. japonica, Gr. DN127, B. an-
dersonii, B. tanukii and B. turdi,
have been named and even more
have been recognized (Baranton et al.
1998). However, only three of them,
B. burgdorferi sensu stricto, B. garinii
and B. afzelii are unambiguously pat-
hogenic to humans. All these three
pathogenic species are found in Eu-
rope and also in Finland. In this stu-
dy B. burgdorferi sensu lato is collec-
tively called B. burgdorferi.
Morphology of B. burgdorferi
B. burgdorferi is a motile gram-negati-
ve helical bacterium with approxima-
tely 7-11 flagellae in its periplasmic
space (Figure 2.). The cells are 8 to 22
microns long, 0.25-0.30 microns wide
and composed of 3-10 loose coils. The
cytoplasmic membrane is trilaminar
and closely approximated to the cell
wall. (Barbour et al. 1986) The major
outer surface proteins are lipoproteins.
Similar to other spirochetes, under
unfavourable conditions B. burgdorfe-
ri forms spheroids or bleb-like struc-
5tures, the function of which has not
been determined. The spheroids may
play a role in the transfer of genetic
material (Dorward et al. 1991).
Figure 2. Borrelia burgdorferi is a heli-
coid gramnegative bacterium
B. burgdorferi can be visualized in CSF,
blood, solid tissues and cultures by
several staining methods, including
Giemsa, carbol-fuchsin and silver im-
pregnation. Gram-staining is less sui-
table, because Borreliae change their
form considerably during fixation and
staining procedures (Wilske et al.
1993). As motile, living organisms B.
burgdorferi can be detected also by
means of dark-field or phase contrast
microscopy. However, these micros-
copic techniques cannot differentiate
the Borrelia species from each other
(Preac-Mursic et al. 1993).
Growth conditions
Microaerophilic B. burgdorferi spi-
rochetes grow slowly in vitro, dividing
every 8 to 12 hours (Barbour 1984).
One essential step in the success of the
initial isolation of B. burgdorferi by
Burgdorfer et al. was the earlier work
of Richard Kelly, who described a suc-
cessful primary cultivation of the tick-
borne relapsing fever spirochete Bor-
relia hermsii in a complex artificial me-
dium (Kelly 1971). Modifications of
this medium, Barbour-Stoenner-Kelly
(BSK-II) (Barbour et al. 1983) and mo-
dified Kelly medium Preac-Mursic
(Preac Mursic et al. 1986) are now used
in the cultivation of B. burgdorferi from
ticks, other vectors, reservoir animals
and patients.
Molecular biology of B. burgdorferi
The whole genome of B. burgdorferi
has been cloned and sequenced. The
function of most of the genes, howe-
ver, is still unknown (Fraser et al.
1997). The genome of B. burgdorferi
is composed of one linear chromo-
some of 950 kb (Baril et al. 1989), li-
near plasmids, and supercoiled cir-
cular plasmids (Barbour et al. 1987;
Hyde et al. 1988). Both the linear and
circular plasmids can be lost during
in vitro cultivation and result in de-
creased infectivity of the bacteria.
Molecular analysis of B. burgdorferi
has concentrated on the characteri-
zation of proteins. The impetus for
6this direction has been the need to
find molecular determinants to iden-
tify different B. burgdorferi isolates
and to distinguish them from other
species. The need to identify antigens
for more specific and more sensitive
serologic tests and for the develop-
ment of vaccines has been another
important motivation for studying B.
burgdorferi proteins. The lipid and
carbohydrate components of borre-
lia are by far less well known than
its proteins.
About 40 immunoreactive bands are
obtained from sodium dodecyl-
sulphate (SDS) lysates of whole cells
of B. burgdorferi in SDS polyacryla-
mide gel electrophoresis (Hauser et
al. 1997). The 60 kDa polypeptide
p60, also designated as “common
antigen“, and the 41 kDa polypepti-
de p41, which represents the flagel-
lin, belong to the most prominent
borrelial antigens. However, proteins
cross-reactive with them occur in se-
veral bacterial antigens even outsi-
de the genus Borreliae (Hansen et al.
1988; Bruckbauer et al. 1992).
The immunodominant proteins of B.
burgdorferi are lipoproteins in the
outer membrane within molecular
weights from 20 to 35 kDa and de-
signated as outer surface proteins
(Osp) A-F. The expression of Osps
varies between isolates and the Osps
are immunologically and genetical-
ly variable (Barbour et al. 1986; Wils-
ke et al. 1993; Wilske et al. 1996). Osps
A, B and C are highly immunogenic.
Osp C and flagellar protein p41 are
the major immunodominant proteins
in early LB, whereas Osp A appears
in the later course of the disease
(Howe et al. 1985; Wilske et al. 1993).
Other specific antigens frequently
recognized in patients with LB in-
clude proteins p83/100, p58, p43,
p39, p30, p21, p17 and p14 (Hauser
et al. 1997).
2.3. Ecology and epidemiology of
Lyme borreliosis
I. ricinus - principal vector of B.
burgdorferi
I. ricinus, also known as the sheep
tick or Castor bean tick, is the most
common tick in Europe and it is res-
ponsible for the transmission of LB
to humans (Figure 3).
Other members of the subgenus Ixo-
des are also capable of transmitting
spirochetes to their hosts. These spe-
cies include I. dammini, I. scapularis,
I. pacificus, I. dentatus and I. neotomae
in North America and I. persulcatus
7Figure 3. Adult female (A), adult male (B)
and a nymph (C) Ixodes ricinus tick from a
Helsinki city park. (Photo: M. Peltomaa)
–
in Europe and northern Asia. (So-
nenshine 1993). The distribution of the
Ixodid ticks is presented in Figure 4.
Figure 4. Geographical distribution of
Ixodid ticks
Other I. ricinus-associated human
pathogens include, among others,
tick-borne encephalitis (TBE) virus,
louping ill virus, Ehrlichia species,
Uukuniemi-virus, Babesia divergens,
Babesia microti and Francisella tularen-
sis. In Europe and North America 18
and 19 different tick species, respec-
tively, are able to transmit B. burgdor-
feri, (Lise Gern, personal communi-
cation).
In addition to ticks other vectors can
also transmit B. burgdorferi, including
the biting fly (Luger 1990; Oksi et al.
1994), mosquitoes (Sinton et al. 1939;
Magnarelli et al. 1986; Halouzka et
al. 1998) and fleas (Doby et al. 1991).
Life cycle of I. ricinus
The length of the life cycle of the I.
ricinus tick varies greatly in the geo-
graphic range of the tick, but it ge-
nerally takes 2-6 years. In northern
parts of its geographic range, as in
Scandinavia, the four-staged life
cycle (egg, larva, nymph and adult)
usually takes 2-4 years (Gray 1991;
Sonenshine 1993). The three latter
motile stages of I. ricinus have a bi-
modal seasonal host seeking pattern
with peaks in late spring or early
summer and in late summer or early
fall (Milne 1943; Milne 1946; Milne
1950; Lees et al. 1951).
Reservoirs of B. burgdorferi
The major reservoirs of B. burgdorferi
are small and medium–sized mam-
mals. In Europe 9 small mammals,
A A
BC
87 medium–sized mammals and 16
bird species are known to be capable
of acting as sources of spirochetes to
ticks (Gern et al. 1998). The most nu-
merous of the reservoir animals in
the zoonotic cycle of B. burgdorferi are
small rodents of the genera Peromys-
cus, Apodemus and Clethrionomys. Va-
rious, especially ground-foraging
birds including thrushes, blackbirds,
robins, wrens and pheasants have
been shown to be reservoirs of B.
burgdorferi (Olsen et al. 1995; Gern et
al. 1998). The prevalence of different
genospecies varies in different reser-
voir animals in Europe and Asia. B.
valaisianae and B. garinii occur prefe-
rentially in birds (Humair et al. 1998),
B. afzelii in small mammals (Humair
et al. 1995; Humair et al. 1998) and B.
burgdorferi sensu stricto and B. garinii
in squirrels (Humair et al. 1998). In
addition to reservoir hosts, which are
capable of transmitting B. burgdorfe-
ri to ticks, there are hosts that either
have a zooprophylactic effect by
destroying spirochetes in the ticks
feeding on their blood (Lane et al.
1998) or serve as inadequate hosts by
favoring certain genospecies, as is the
case with birds, which harbor B. ga-
rinii and B. valaisianae, but not B. af-
zelii (Kurtenbach et al. 1998).
Infestation of I. ricinus with B.
burgdorferi sensu lato
All of the I. ricinus populations that
have been examined in Europe have
harbored B. burgdorferi sensu lato. A
critical analysis of 79 European studies
on the infestation rates of ticks with B.
burgdorferi showed rates of 2.8%
(n=3 210), 13.8% (n=31 288) and 21.1%
(n=27 421) for larval, nymphal and
adult ticks, respectively (Hubalek et al.
1998). In the northeastern part of the
United States, 25-50% of the nymphal
and more than 50% of the adult I. sca-
pularis ticks harbor B. burgdorferi (Bos-
ler et al. 1984; Piesman et al. 1986).
Determinations of the prevalence of B.
burgdorferi in I. ricinus in Finland sho-
wed these spirochetes to be present in
all the tick populations studied. All
three human pathogen genospecies
are found in Finnish ticks; however, B.
burgdorferi sensu stricto has been iso-
lated only from the Åland islands in
the southwestern archipelago of Fin-
land (Junttila et al. 1994; Tuomi et al.
1995).
Transmission of B. burgdorferi by I.
ricinus to humans
Tick bites are common among hu-
mans and LB affects both males and
females in all age groups, although
9the clinical picture of LB is different
in children and adults. The bimodal
seasonal activity of the I. ricinus cor-
responds with the seasonal variati-
on of early clinical cases. The pain-
less tick bite often remains unnoti-
ced, and only about 30-50% of the
patients with clinical LB recall having
been bitten (Weber et al. 1983; Weber
et al. 1986). Although nymphal ticks
are less frequently infected than
adult ticks, they are more numero-
us, smaller and more easily unnoti-
ced and therefore seem to be the
main vector of human LB.
B. burgdorferi resides in the midgut
of the ungorged tick. Penetration of
the gut epithelium and disseminati-
on into other tissues take place du-
ring early feeding and reach maxi-
mum in 1-2 days (De Silva et al.
1995). The transmission of B. burgdor-
feri seems to occur from contact with
the saliva of the tick (Ribeiro et al.
1987) rather than by regurgitation of
the gut content (Burgdorfer 1984).
The transmission of B. burgdorferi into
laboratory animals usually occurs 36-
48 hours after tick attachment (Pies-
man 1993; Shih et al. 1995). The
prompt removal of tick from the skin
can thus diminish the risk of infecti-
on (Kahl et al. 1998). On the other
hand, the possibility of rapid trans-
mission has also been suggested
(Piesman 1995). The best method for
tick removal remains controversial
(Kahl et al. 1998). Despite the high
mean infestation rates of ticks with
B. burgdorferi, the risk of developing
LB after a tick bite is low, less than
1% in Europe (Paul et al. 1989) and
from 1% to 5% in the United States
(Magid et al. 1992; Shapiro et al.
1992).
2.4. Pathogenesis of Lyme
borreliosis
Lyme borreliosis in animals
The investigation of the pathogene-
sis of LB has been hampered by a lack
of an animal model that adequately
mimicks the stages of human dise-
ase (Hu et al. 1997). Numerous ani-
mals, including mice, rats, gerbils,
hamsters, rabbits, dogs, cows and
monkeys have been used to develo-
pe an animal model for human LB.
Animals can be infected naturally by
letting them be bitten by infected
ticks or inoculating spirochetes eit-
her intradermally, subcutaneously,
intravenously or intraperitoneally.
The susceptibility of laboratory ani-
mals in developing clinical infection
after B. burgdorferi inoculation varies
considerably. Infection can also be
10
present in an animal without clini-
cal signs of the disease (Barthold et
al. 1988).
Proliferation and dissemination of B.
burgdorferi in humans
B. burgdorferi spreads readily from
the site of primary infection to other
parts of the body, either via blood
circulation (Berger et al. 1994) or di-
rectly by tissue invasion (Christen et
al. 1993). The progression from local
skin infection to disseminated LB can
occur already in the early phase of
the disease. For example, B. burgdor-
feri has been isolated from the blood
4 days after the tick bite (Steere et al.
1983) and two days after the appea-
rance of EM (Benach et al. 1983). The
cultivation of B. burgdorferi from the
blood is rarely successful, and there-
fore a rapid clearing of the spiroche-
tes from circulation is suggested
(Galbe et al. 1993).
Host pathogen interaction in Lyme
borreliosis
After entering the human body, B.
burgdorferi elicits a series of events in
the host, which attempt to destroy
the invader or limit its spread to ot-
her parts of the body. These events
include accumulating inflammatory
cells around the skin lesion and in-
ducting immune response. The cent-
ral paradox in the pathogenesis of B.
burgdorferi is its ability to persist des-
pite the defense mechanisms of the
mammalian host. Tick´s saliva con-
tains factors that impair a range of
proinflammatory responses in the
host and promote the infectivity of
B. burgdorferi (Zeidner et al. 1996).
B. burgdorferi is able to bind in vitro
to various receptors present on nu-
merous cells, including certain pro-
teoglycans, glycosphingolipids and
glycosaminoglucans, which may al-
low specific tissue tropism. All B.
burgdorferi genospecies can cause si-
milar clinical symptoms, but B. afze-
lii is found to be predominant among
European skin isolates, and B. garinii
prevails among isolates recovered
from patients with neurological
symptoms (Saint Girons et al. 1998;
Picken et al. 1998).
In the absence of its own enzymes,
B. burgdorferi can utilize host enzy-
mes in spreading through the skin
and other tissues. The spirochete is
capable of binding human plasmi-
nogen and its activator urokinase
(Fuchs et al. 1996; Coleman et al.
1997). These enzymes can then en-
hance its penetration through endot-
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helial cell layers (Szczepanski et al.
1990) and enable the spirochetes to
disseminate into various organs
(Garcia-Monco 1998).
Although B. burgdorferi resides clear-
ly in the extracellular compartment
of the mammalian host, it has been
found also inside endothelial cells,
fibroblasts, synovial cells and macro-
phages (Ma et al. 1991; Klempner et
al. 1993; Montgomery et al. 1993; Gir-
schick et al. 1996). Treatment failu-
res have been proposed to be due to
either an intracellular location of the
spirochete or to the location of the
organism in “a protected site“, such
as the central nervous system (CNS)
(Hu et al. 1997).
In tick midgut the major outer surface
protein of B. burgdorferi is OspA, whe-
reas in the mammalian host the pro-
duction of OspA is down-regulated
and the production of OspC is up-re-
gulated (de Silva et al. 1996; Montgo-
mery et al. 1996). This antigenic mo-
dulation may help the pathogen to
evade the host immune system.
Immune response to B. burgdorferi
Humoral immunity appears to be the
host´s most effective defense against
B. burgdorferi (Hu et al. 1997). The
development of specific antibodies
follows the classical pattern of IgM
response preceding IgG and IgA res-
ponses. During the first 2-4 weeks in
early, localized infection (EM) less
than half of the patients produce
measurable levels of antibodies to B.
burgdorferi. IgM antibodies rise com-
monly during the 3rd week, peak af-
ter 4 to 6 weeks, and disappear a
couple of weeks later (Craft et al.
1984). IgG antibodies appear after 6
weeks of infection and can increase
for months to years. IgG antibodies
often persist for years or decades.
Sometimes even IgM antibodies can
persist for months to years. Antibo-
dy response to B. burgdorferi, howe-
ver, can (but rarely) be weak or ab-
sent at different stages of the disease
in some patients (Dattwyler et al.
1988; Steere 1993; Oksi et al. 1995).
The humoral immune response in LB
is characterized by the initial recogni-
tion of a limited number of antigens,
followed by a marked expansion in the
repertoire of antigens recognized later
in the course of illness (Craft et al.
1986). The earliest antibody responses
are usually directed against the 21 kDa
OspC protein, the 41 kDa flagellar an-
tigen, a 39 kDa antigen and the 58 kDa
antigen (Simpson et al. 1990; Dressler
et al. 1993). In the United States, the
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Centers for Disease Control and Pre-
vention (CDC) (1996) recommends
Western blotting as a confirmatory test
for positive results of borrelia antibo-
dies in ELISA. However, in Europe
generally accepted interpretation cri-
teria have not yet been established for
Western blotting (Hauser et al. 1997).
A specific T-cell response is detectab-
le early in the course of LB, often pre-
ceding the humoral immune respon-
se (Dattwyler et al. 1986). The use of
cell-mediated immune responses in
the diagnosis of various clinical ma-
nifestations of LB remains, however,
controversial. T-cells reactive with
the antigens of B. burgdorferi may
cross-react with many other antigens
(Volkman et al. 1991), and cell proli-
feration assay is not considered as
sensitive tool as antibody measure-
ment in the diagnosis of LB (Datt-
wyler et al. 1988).
2.5. Clinical spectrum of Lyme
borreliosis
Description of Lyme borreliosis by
stages
The clinical picture of LB varies con-
siderably in individual patients.
However, epidemiological observa-
tions have led to the concept of the
development of LB in three different
stages, including early stages I and
II and late stage III (Steere et al. 1984;
Åsbrink 1991). The hallmark of sta-
ge I, and of the disease in general, is
EM, the pathognomonic expanding
erythematous rash on the site of the
tick bite. Stage II includes early dis-
seminated infection with a broad
spectrum of symptoms. The stage III
is the late phase of infection with
chronic neurological, dermatological
or inflammatory joint symptoms.
The three stages overlap considerab-
ly, however, and are often difficult to
differentiate. A more practical and
pathophysiologically valid staging of
LB into early localized and dissemi-
nated disease has been proposed
(Halperin 1995).
Erythema migrans and other early
signs and symptoms
EM, previously called erythema
chronicum migrans, starts as a mac-
ula or papule expanding over a peri-
od of days to weeks (Figure 5.). In 30-
50% of the cases EM is preceded by a
recognized tick bite and rarely by a
sting of a flying insect (Weber et al.
1983; Åsbrink et al. 1988; Oksi et al.
1994). The tiny and easily unnoticed
nymphal tick is probably the respon-
sible vector in cases without any his-
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Figure 5. Slowly expanding rash, Erythe-
ma migrans is the hallmark of early Lyme
borreliosis. (Photo: Department of Derma-
tology, Helsinki University Central Hos-
pital)
–
tory of previous tick bite. An EM les-
ion is often asymptomatic, but the pa-
tient can, however, experience pain,
burning, heat or mild itching (Weber
et al. 1993). The shape and outlook of
EM varies. The initial lesion is usually
homogeneous, red or bluish red with
a round or oval shape. About 70% of
the patients with EM present with con-
stitutional symptoms like fatigue,
headache, fever, arthralgia and myal-
gia (Weber et al. 1986). With the excep-
tion of regional lymphadenopathy and
fever, objective findings are rare in the-
se patients (Weber et al. 1993; Nadel-
man et al. 1995). The enlargement of
EM varies considerably, and, if left
untreated, the lesion commonly ex-
ceeds a diameter of 15 centimeters or
more. EM usually resolves sponta-
neously in a few weeks or months, but
without treatment it can reappear la-
ter (Weber et al. 1993).
In Europe 4-8% (Weber et al. 1993)
and in North America up to 50%
(Steere et al. 1983) of the patients with
LB develop multiple EM lesions as
the sign of disseminated disease.
Borrelial lymphocytoma and acro-
dermatitis chronica atrophicans
Borrelial lymphocytoma is a rare skin
manifestation, and it has been re-
ported in connection with LB only in
Europe (Hovmark et al. 1993). It is a
bluish-red, tumorlike skin infiltrate,
usually 1-5 centimeter in diameter.
Lymphocytoma is usually located on
the earlobe, nipple or scrotum, and
it occurs more frequently in children.
Untreated lymphocytoma resolves
spontaneously, but it may take up to
1 year and result in sequelae (Hov-
mark et al. 1993).
ACA is a late skin manifestation of LB
and has been described mainly in Eu-
rope. It is a bluish-red, atrophic lesion,
that is sometimes complicated by scle-
rodermic changes. It typically starts in
later decades of life and occurs predo-
minantly in women (Åsbrink 1993).
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The predilection sites of ACA are dis-
tal extensor surfaces of the limbs. Ex-
tracutaneous manifestations, such as
peripheral (Kaiser 1972) and central
neuropathy (Sandström et al. 1989)
and joint manifestations (Hovmark et
al. 1986), are not uncommon concomi-
tantly with ACA.
Musculoskeletal manifestations
Arthritis is a relatively frequent mani-
festation of LB. However, the inciden-
ce figures from various countries and
from studies representing various spe-
cialities are not always comparable
because of bias caused by patient se-
lection (Herzer 1993). Lyme arthritis
(LA) is characterized by recurrent brief
attacks of objective joint swelling in
one or a few joints, occasionally prog-
ressing to chronic arthritis (Cimmino
et al. 1998). In the United States about
60% of the patients with untreated EM
later develop episodes of LA (Steere
1989). B. burgdorferi can only rarely be
isolated from the joints of patients with
LA. In most cases the pathogenesis is,
however, associated with the presen-
ce of spirochetes in the joints (Nocton
et al. 1994). In some patients with chro-
nic, treatment-resistant LB, autoimmu-
ne mechanisms can play a role in the
pathogenesis of the disease. Antibo-
dies to OspA and OspB have been lin-
ked to the development of chronic
arthritis (Kalish et al. 1993). The con-
cept molecular mimicry, whereby bac-
terial antigens share epitopes with host
proteins, has been proposed as one
mechanism of the chronic inflamma-
tion in patients with chronic LB (Sigal
et al. 1988; Garcia-Monco et al. 1993;
Sigal 1993).
Arthralgia and myalgia occur in
most patients with early LB in North
America, but only in every fifth pa-
tient in Europe (Steere et al. 1983;
Weber et al. 1986). These symptoms
alone, however, are not criteria for
the musculoskeletal involvement of
LB (Stanek et al. 1996). Other mus-
culoskeletal manifestations asso-
ciated with LB include myositis (Sch-
mutzhard et al. 1986; Reimers et al.
1993) and osteomyelitis (Jacobs et al.
1986; Oksi et al. 1994). LB can trigger
fibromyalgia (Dinerman et al. 1992),
which, however, not rarely seems to
be misdiagnosed as LB (Sigal et al.
1992; Steere et al. 1993; Hsu et al.
1993).
Neurological and otoneurological
manifestations
Early neurological manifestations of
LB include meningitis, cranial and
peripheral nerve neuropathies and
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Bannwarth´s syndrome, which is
characterized by painful meningora-
diculoneuritis with lymphocytic
pleocytosis in the CSF with or with-
out peripheral paresis and with or
without cranial nerve affection (Pfis-
ter et al. 1993). Patients with Lyme
meningitis in Europe usually do not
suffer from meningeal symptoms
(Garcia-Monco 1992). In the United
States, however, most of the patients
have meningeal symptoms, such as
headache and mild neck stiffness
(Reik et al. 1979; Pachner et al. 1985).
The clinical picture of Lyme menin-
gitis resembles acute aseptic menin-
gitis, but it can also take a long-term
or relapsing course (Stiernstedt 1985;
Pachner et al. 1985).
Cranial neuropathies develop in 47%
to 82% of LB patients without anti-
biotic treatment (Pfister et al. 1993).
FP accounts for 70% to 80% of cra-
nial neuropathies that occur in LB
(Reik 1991) and it is the most com-
mon single neurologic symptom of
LB.
Chronic CNS abnormalities are rare
in LB, and they develop months to
years after the initial infection (Han-
sen et al. 1992). Late CNS LB inclu-
des all forms of encephalitis, en-
cephalomyelitis, meningoencephali-
tis and radiculitis (Kristoferitsch
1991; Hansen et al. 1992; Martin et al.
1993). Chronic disease often affects
peripheral nerves also. As much as
40% to 63% of patients with ACA
suffer from concomitant chronic pe-
ripheral neuropathy (Åsbrink 1985;
Kristoferitsch et al. 1988).
Cardiac manifestations
Lyme carditis is estimated to occur
in 8% of patients with LB in North
America (Steere et al. 1980). In Euro-
pe the frequency of cardiac manifes-
tations has not yet been established
(van der Linde et al. 1993). Lyme car-
ditis can occur as rhythm or conduc-
tion abnormalities, endomyocarditis
and pericarditis either with or with-
out heart failure (van der Linde et al.
1993). An atrio-ventricular block of
fluctuating degree is the most com-
mon sign of Lyme carditis, but also
total atrio-ventricular block occurs
(Steere et al. 1980; Olson et al. 1986).
The role of B. burgdorferi in chronic
heart disturbances is unclear, but the
significantly higher prevalence of
positive levels of antibodies to B.
burgdorferi in patients with cardio-
myopathy than in patients with co-
ronary heart disease or healthy blood
donors suggests that there may be an
association between LB and chronic
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heart disease (Klein et al. 1991; Sta-
nek et al. 1991).
Ocular manifestations
In LB the eye can be affected either
by the infection and inflammation of
ocular tissue or by the involvement
of extraocular tissues. Like syphilis,
LB seems to be a great imitator of
various ocular inflammations. Neu-
roophthalmic and ocular manifesta-
tions of LB include cranial neuropat-
hies, optic nerve disease, meningitis
with papilledema, neuroretinitis,
conjunctivitis, keratitis, uveitis, vit-
reitis, and other forms of posterior
segment inflammatory disease (Les-
ser 1995; Karma et al. 1996; Balcer et
al. 1997; Mikkilä et al. 1997; Mikkilä
et al. 1997; Zaidman 1997). Intraocu-
lar inflammations caused by B. burg-
dorferi are rare and difficult to diag-
nose (Schönherr et al. 1993). In en-
demic areas LB is not an extreme ra-
rity among patients with uveitis or
posterior segment inflammations of
unknown etiology and it should be
taken into account in the diagnostic
work-up (Mikkilä 1998).
Other manifestations
B. burgdorferi disseminates hemato-
genously, and several organs can be
infected. Subclinical hepatitis with
elevated serum transaminases (Kaza-
koff et al. 1993), splenomegaly (Cim-
mino et al. 1989; Nelson et al. 1992),
orchitis, testicular swelling, micro-
scopic hematuria, and proteinuria
(Steere 1989) have been reported in
patients with LB.
2.6. Diagnosis of Lyme borreliosis
Typical signs and symptoms of the
patient are the cornerstone of the
diagnostics of LB. If pathognomonic
symptoms, such as EM, are present,
the diagnosis is straightforward and
usually no laboratory tests are nee-
ded. However, many of the numero-
us symptoms of LB are not specific
for the disease, and laboratory met-
hods are necessary to support or con-
firm the diagnosis. These laboratory
methods fall in two categories: indi-
rect methods (including the assess-
ment of antibodies against B. burg-
dorferi and the lymphocyte stimula-
tion test) and direct methods (inclu-
ding cultivation, microscopy and
staining, antigen detection and PCR).
Serological methods
The first serological tests introduced
for the diagnosis of LB were based on
indirect immunofluoroscence (IFA)
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technology (Wilkinson 1984). Later,
ELISA has become the most widely
used screening method in LB diagnos-
tics. Western blotting is recommended
for use in the confirmation of positive
results obtained by ELISA. The anti-
gen preparations used in these tests
include whole cell preparations, so-
nicated cell suspensions, purified fla-
gellin protein and recombinant pro-
teins of B. burgdorferi (Hansen et al.
1988; Burkert et al. 1996). The genetic
variability of B. burgdorferi makes the
selection of appropriate antigens for
the serological tests a challenging task.
The diagnosis of LB by serological tes-
ting suffers from poor standardizati-
on of the methods, which has become
evident in interlaboratory compari-
sons (Tilton 1994; Bakken et al. 1997;
Guy et al. 1998).
Indirect immunofluoresence
IFA is a rather simple procedure and
does not need very sophisticated la-
boratory equipment. In experienced
hands the method has also been ac-
curate (Magnarelli et al. 1984; Rus-
sell et al. 1984). The interpretation of
IFA results can vary, however, becau-
se of the subjectivity of the reading
process. In addition, IFA is less sen-
sitive than ELISA, too laborious for
high-volume testing and prone to
variability in manufacturing proces-
ses (Stiernstedt et al. 1985; Golightly
1993; Tilton 1994).
Enzyme linked immunosorbent assay
ELISA is the most widely used met-
hod for assessing antibodies against
B. burgdorferi. This method, as well
as other serological tests is hampe-
red, however, by the occurrence of
cross-reacting antibodies and a lack
of sensitivity, especially in the early
phases of LB (Bruckbauer et al. 1992).
ELISA tests are available as both in-
house assays and commercial kits.
Numerous antigens have been tested
in attempts to improve the efficacy
of ELISA. Sonicated bacteria are wi-
dely used for screening purposes,
usually combined with purified or
recombinant antigens for confirming
positive results (Burkert et al. 1996;
Guy et al. 1998). Immunological and
molecular biological investigations
have revealed and characterized a
variety of borrelial antigens, inclu-
ding p83/100, p66, p41 (flagellin),
p39 (BmpA), p17 and outer surface
proteins OspA, OspB, OspC, OspD,
OspE and OspF. In early infection,
the immune response is mainly re-
stricted to p41 (Craft et al. 1986) and
OspC (Wilske et al. 1986). Later, du-
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ring the course of prolonged infecti-
on, the immune response is directed
against tens of different antigens.
This phenomenon can best be de-
monstrated by Western blotting with
which sera from patients with late LB
can show as many as 40 immuno-
reactive bands (Hauser et al. 1997).
Several reports have been published,
however, on seronegative patients
with definite LB (Dattwyler et al.
1988; Guy et al. 1989; Schutzer et al.
1990; Oksi et al. 1995). ELISA, as well
as other serological methods, are
more sensitive in late than early sta-
ges of the disease. In the diagnosis
of late European LB, the most speci-
fic diagnostic antigens for ELISA in-
clude p83/100, p58, p43, p39, p30
OspC, p21, p17 and p14 (Hauser et
al. 1997). Several important proteins
are immunologically variable in dif-
ferent genospecies of B. burgdorferi.
Thus the use of purified antigens
does not solve the problem caused
by antigen polymorphism. In the fu-
ture, carefully designed antigen
cocktails should be constructed for
ELISA to cover different B. burgdor-
feri genospecies as well as possible.
Western blotting
Ideally, all positive ELISA results
should be confirmed by Western
blotting (Tilton 1994). In the United
States the CDC recommend a two-
step protocol for the evaluation of the
sera. ELISA should be performed for
screening, and positive results
should be confirmed by Western
blotting assay according to the crite-
ria accepted by the CDC (Centers for
Disease Control and Prevention
1995). In Europe, however, general-
ly accepted criteria have not been
established. The three known B. burg-
dorferi strains pathogenic for human
and at least eight different serotypes
present in Europe make the definiti-
on of Western blotting criteria more
complicated. Attempts have recent-
ly been made to establish European
criteria, however (Hauser et al. 1997).
Cultivation
B. burgdorferi requires a special me-
dium for growth. BSK-II medium was
the first described for this purpose; la-
ter several modifications of it have
been developed (Barbour et al. 1983;
Preac Mursic et al. 1986). B. burgdorferi
is a slowly growing organism, and so-
metimes cultivation has to be conti-
nued for weeks to obtain detectable
growth. Although B. burgdorferi has
been isolated from specimens obtained
at all stages of LB, isolation is more
successful at early stages than later.
19
B. burgdorferi has been isolated from a
variety of body tissues, including skin
(Steere et al. 1983; Åsbrink 1985; Sta-
nek et al. 1985) blood (Benach et al.
1983; Viljanen et al. 1992), CSF (Steere
et al. 1983; Karlsson et al. 1990), syno-
vial fluid and synovial membrane
(Snydman et al. 1986; Schmidli et al.
1988), tendon (Haupl et al. 1993), myo-
cardium (Stanek et al. 1990), iris (Preac
Mursic et al. 1993), and subcutaneous
fat (Viljanen et al. 1992). Skin biopsies
from patients with EM have been cul-
ture positive in 60% - 86% of the cases
(Wormser et al. 1992; Berger et al. 1992;
Mitchell et al. 1993). Furthermore, B.
burgdorferi has been cultured from the
sera of 25% of the patients with EM
(Wormser et al. 1998). The sensitivity
of cultivation is much lower for tissu-
es other than EM skin. The yields of
cultivation from the blood of patients
with EM and from the CSF of patients
with neuroborreliosis have been 5% or
less and 7%-10%, respectively (Wilske
et al. 1993; Wormser et al. 1998). Thus,
a negative result in cultivation does not
exclude LB, and the value of this met-
hod in the diagnosis of LB is conside-
red rather limited.
Microscopy
Various specimens have been stained
by Giemsa, silver impregnation and
immunohistochemical techniques
for the microscopical observation of
B. burgdorferi (de Koning et al. 1993).
However, microscopy is time consu-
ming, lacks both specificity and sen-
sitivity and is not suitable for the rou-
tine diagnosis of LB.
Polymerase chain reaction
PCR is a powerful method for detec-
ting small amounts of nucleic acids.
It has been used to detect B. burgdor-
feri in ticks (Persing et al. 1990) and
in a wide variety of human and ani-
mal specimens (Picken et al. 1997).
PCR has many advantages, inclu-
ding high sensitivity, specificity and
rapidity. The extreme sensitivity can,
however, cause false positive results
because of contamination. This prob-
lem can generally be controlled by
careful attention to controls and la-
boratory procedures. On the other
hand, false negative results can be
caused by inhibitors in the specimens
or simply by the fact that not a sing-
le bacterium has reached the minute
proportion of the specimen subjected
to PCR analysis. In practice, the re-
ports on PCR from human tissues
and body fluids show controversial
results (Schmidt 1997). Neither the
ideal type of specimen nor the selec-
tion of primers for the optimal de-
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tection of borrelial DNA in patients
is known. In optimized conditions
PCR from EM and ACA skin biopsi-
es have reached sensitivities of 100%
(Schempp et al. 1993; Moter et al.
1994). In practice the sensitivity of
PCR for body fluids and tissues is
much lower and varies considerably
depending on the specimen obtained
and PCR method used (Schmidt
1997). The routine use of PCR in the
diagnosis of LB is far from being ge-
nerally accepted, but it is a promising
method for a more reliable and fas-
ter confirmation of LB.
Lymphocyte proliferation test
B. burgdorferi infection usually also
induces cell-mediated immune res-
ponse, which can be detected in vit-
ro by the lymphocyte proliferation
test (Dattwyler et al. 1986). This test
can be helpful in the diagnosis of late
LB in the small subset of patients
with no or weak antibody responses
(Dressler et al. 1991). However, the
test has several limitations. It is con-
sidered less sensitive than the measu-
rement of antibodies, and it can pro-
duce false positive results because of
cross-reactive immunity against
microbes antigenically resembling B.
burgdorferi (Dattwyler et al. 1988).
Thus a negative result in a lympho-
cyte stimulation test does not exclude
LB.
Antigen detection
There is both in vitro and in vivo evi-
dence that B. burgdorferi sheds ve-
sicles containing DNA from its sur-
face membrane, and also surface-as-
sociated proteins (Barbour et al. 1986;
Garon et al. 1989). B. burgdorferi anti-
gens have been detected in urine,
CSF, blood, and tissue specimens
with ELISA, Western blotting and
electron microscopy (Benach et al.
1988; Garcia-Monco et al. 1990; Dor-
ward et al. 1991; Coyle et al. 1993).
Although promising, antigen detec-
tion tests are not available for routi-
ne use. Their limitations include a
lack of standardized reagents and a
lack of controlled clinical studies on
sensitivity and specificity (Coyle
1993).
2.7. Medical treatment of Lyme
borreliosis
Antibiotic susceptibility of
B. burgdorferi
Antibiotics have been used in the treat-
ment of LB since the late 1940s (Bian-
chi 1950; Thyresson 1950; Hollström
1951). Initially the disease was treated
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with penicillin, later with various ot-
her antibiotics. Current knowledge
about the efficiency of individual an-
tibiotics is based on several in vitro and
in vivo studies (Johnson et al. 1984;
Johnson et al. 1987; Luft et al. 1988;
Johnson et al. 1990; Johnson et al. 1990;
Wormser 1990; Preac-Mursic 1993).
The in vitro growth of B. burgdorferi is
inhibited by several antibiotics, such
as amoxicillin, ampicillin, azithromy-
cin, cefotaxime, ceftriaxone, cefuroxi-
me, clarithromycin, doxycycline,
erythromycin, imipenem, penicillin,
roxithromycin and tetracycline
(Wormser 1990). The in vitro effect of
erythromycin is one of the strongest,
whereas the effect of penicillin is rat-
her weak. B. burgdorferi is resistant to
aminoglycosides, rifampin and trime-
toprin-sulfamethoxazole. These in vit-
ro results should be viewed cautious-
ly because the methods used are not
well standardized and there is no proof
that the results correlate with the cli-
nical effectiveness of the drugs (Nowa-
kovski et al. 1993). For example, the
good in vitro efficacy of certain macro-
lide antibiotics contrasts with the re-
sults of clinical trials in humans and
animals, where these drugs have had
an activity lower than that of penicil-
lin and tetracycline (Steere et al. 1983;
Johnson et al. 1990; Hansen et al. 1992;
Luft et al. 1996).
Antibiotic treatment of erythema
migrans
There is evidence that patients with
early LB and even with meningora-
diculoneuritis or meningitis can re-
cover spontaneously (Pfister et al.
1993). Antimicrobial therapy is, how-
ever, always indicated for EM to pre-
vent the development of the more
serious later manifestations of LB
(Weber et al. 1994).
EM disappears usually within a few
days after the start of antimicrobial
therapy. Numerous studies have
been conducted to compare the effi-
cacy of different antibiotic agents in
the treatment of EM and the preven-
tion of late symptoms of LB. In an
early study by Steere et al., oral pe-
nicillin and tetracycline, but not
erythromycin, reduced the duration
of EM (Steere et al. 1980). In a subse-
quent study by the same group, tet-
racycline was superior to oral penicil-
lin and oral penicillin was superior
to erythromycin in preventing minor
late complications (Steere et al. 1983).
As other researchers later, Steere et
al. showed a positive correlation bet-
ween the severity of initial symptoms
and the outcome of LB (Steere et al.
1983; Weber et al. 1987; Weber et al.
1990).
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In comparative studies oral penicil-
lin, tetracycline and amoxicillin/cla-
vulanate (Weber et al. 1988), amoxi-
cillin/probenecid and doxycycline
(Dattwyler et al. 1990), doxycycline,
amoxicillin/probenecid and azithro-
mycin (Massarotti et al. 1992), cefu-
roxime axetil and doxycycline (Na-
delman et al. 1992), azithromycin and
penicillin (Weber et al. 1993), azithro-
mycin and doxycycline (Strle et al.
1996) and penicillin and minocycli-
ne (Breier et al. 1996) have been
found equally effective in the treat-
ment of EM.
Ceftriaxone was as effective as oral
penicillin in the treatment of EM in a
study which also noted that ceftria-
xone was superior to penicillin in a
subgroup of patients with more than
one symptom prior to therapy (We-
ber et al. 1990). In the study con-
ducted by Strle (Strle et al. 1992),
azithromycin was superior to doxy-
cycline and oral penicillin in terms
of the resolution of EM-associated
local and systemic symptoms. In
another study amoxycillin was supe-
rior to azithromycin (Luft et al. 1996).
Even though antimicrobial therapy
has been used for EM, mild or seve-
re other manifestations of LB can
develop (Weber et al. 1994). Most, if
not all, antibiotics used thus far have
been associated with treatment fai-
lures in patients with EM (Weber
1996). B. burgdorferi has also been
cultivated from the site of EM after
antimicrobial treatment (Preac Mur-
sic et al. 1989; Strle et al. 1993).
Antibiotic treatment of disseminated
Lyme borreliosis
The beneficial effect of penicillin G
in the therapy of neurological symp-
toms associated with EM was known
in Europe already before the etiolo-
gy of LB was clarified (Hollström
1951; Weber 1974). Most of the pati-
ents with acute borrelial meningitis
and meningoencephalitis can be cu-
red by intravenously administered
penicillin (Kristoferitsch et al. 1987;
Sköldenberg et al. 1988; Pfister et al.
1989; Mullegger et al. 1991; Karlsson
et al. 1994). However, there are re-
ports of progressive disease despite
penicillin therapy (Diringer et al.
1987; Pal et al. 1988; Gourmelen et al.
1989). Lipid soluble doxicycline with
the ability to cross the blood-brain
barrier (Karlsson et al. 1996) has been
shown to be equally effective as pe-
nicillin G in cases of neuroborrelio-
sis (Karlsson et al. 1994). Penicillin-
resistant neuroborreliosis has suc-
cessfully been treated with ceftriaxo-
ne (Dattwyler et al. 1987), chlo-
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ramphenicol (Diringer et al. 1987)
and cefotaxime (Pal et al. 1988).
Little information is available about
the antibiotic treatment of late bor-
relial encephalomyelitis and cerebral
vasculitis (Weber et al. 1994). Symp-
toms and sometimes signs of late
peripheral neuropathy have impro-
ved after therapy with intravenous
penicillin or intravenous cephalospo-
rins (Weber et al. 1994).
LA has a tendency to resolve sponta-
neously over the years (Steere 1989).
Antibiotic therapy is, however, always
indicated. Benzathine penicillin and,
especially, intravenous penicillin can
cure LA (Steere et al. 1985; Huaux et
al. 1988). A study comparing intrave-
nous penicillin and intravenous ceft-
riaxone in the treatment of patients
with late LB, including patients with
arthritis and arthralgia, suggested the
superiority of ceftriaxone (Dattwyler
et al. 1988). From one-third up to two-
thirds of the patients with LA have res-
ponded to oral treatment with penicil-
lin (Schaad et al. 1986), doxicyclin
(Schaad et al. 1986; Liu et al. 1989) or
amoxicillin/probenecid (Liu et al.
1989).
Recommendations for the antimicro-
bial treatment of Lyme borreliosis
The optimal treatment of various
forms of LB is unknown. Most of the
therapeutic trials have drawbacks if
evaluated critically, and their results
have to be interpreted with caution
(Weber et al. 1993).
The recommendations for the treat-
ment of EM and associated symp-
toms (Stage I of LB) include oral
phenoxymethylpenicillin (1.5 million
IU three times a day), amoxicillin
(500mg three or four times a day) and
doxycycline (200 mg a day) for 2-4
weeks (Rahn et al. 1991; Sigal 1992;
Weber et al. 1994). For patients with
intolerance to penicillin or tetra-
cyclin, cefuroxime axetil or azithro-
mycin may be an alternative (Nadel-
man et al. 1992; Weber 1996). Ro-
xithromycin and erythromycin seem
to be ineffective in the treatment of
EM (Weber 1996). Intravenous ceft-
riaxone is recommended for patients
with EM accompanied by severe as-
sociated symptoms (Weber et al.
1993). In early disseminated LB with-
out meningitis oral doxycycline is an
alternative to intravenous ceftriaxo-
ne (Dattwyler et al. 1997).
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Patients with Bannwarth´s syndrome
and meningitis are usually recom-
mended to be treated with intrave-
nous antimicrobial therapy. Ceftria-
xone (2 g once daily) or other third-
generation cephalosporins seem to
be appropriate therapy for early neu-
roborreliosis (Weber et al. 1994). Oral
doxycycline has also been used suc-
cessfully in the treatment of neuro-
borreliosis (Karlsson et al. 1994). The
duration of the intravenous therapy
for late LB is often 2-3 weeks, and
many authorities consider therapies
longer than 4 weeks rarely indicated
(Steere 1989; Rahn et al. 1991; Sigal
1992; Weber et al. 1994).
Penicillin, amoxicillin, azithromycin
and tetracycline have been used suc-
cessfully for the treatment of borre-
lial lymphocytoma. (Hovmark et al.
1986; Strle et al. 1996). However, con-
clusive data on the efficacy of these
drugs in this respect are not availab-
le (Weber et al. 1993; Strle et al. 1996).
The recommendations for the anti-
microbial therapy of EM are widely
considered valid also for the thera-
py of borrelial lymphocytoma.
For several decades, ACA has been
successfully treated with penicillin
and later also with tetracyclines. Pe-
nicillin or doxycycline courses of 30
days were superior to a 2-week cour-
se of intravenous ceftriaxone in the
eradication of B. burgdorferi in pati-
ents with ACA (Aberer et al. 1996).
2.8. Prevention of Lyme borreliosis
LB is, to a large extent, a preventable
infection. Avoidance of heavily tick-
infested areas, personal protection
with proper clothing, and prompt
removal of attached ticks remain the
most effective protective measures.
Many other preventive measures are
available and could be efficiently
used to reduce the abundance of vec-
tors. However, since the ecology of
B. burgdorferi varies greatly between
different localities, it may be neces-
sary to apply different combinations
of control methods in different ende-
mic regions (Jaenson et al. 1991).
The risk of borrelial infection after a
single tick bite is low (1%-3.5%)
(Warshafsky et al. 1996). Several tri-
als with antimicrobial prophylactics
after Ixodes tick bites have been con-
ducted in endemic areas (Costello et
al. 1989; Magid et al. 1992; Shapiro
et al. 1992; Agre et al. 1993; Warshafs-
ky et al. 1996; Sood et al. 1997; Fix et
al. 1998). No trial, however, and not
even a meta-analysis of published
trials, has statistically significantly
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demonstrated the efficacy of anti-
microbial treatment in preventing LB
after tick bites. Even though anti-
microbial therapy is not recommen-
ded by scientists as a prophylactic
measure, a considerable percentage
of physicians use it (Eppes et al. 1994;
Ziska et al. 1996). A recent study sho-
wed that tick identification and the
measurement of engorgement can be
used to identify a small, high-risk
subset of persons who may benefit
from the immediate administration
of an antibiotic (Sood et al. 1997). The
awareness of the local infestation ra-
tes of ticks with B. burgdorferi may
help to identify the high-risk areas.
Vaccination for Lyme borreliosis
Animal models have shown that both
passive and active immunization can
protect against infection by B. burgdor-
feri (Johnson et al. 1988; Fikrig et al.
1992). Both human and veterinary LB
vaccines are needed in areas endemic
for the disease. A recombinant OspA
vaccine has been licensed for the pre-
vention of LB in dogs (Edelman 1991).
Two extensive efficacy studies of vac-
cines for the prevention of LB have re-
cently been completed in the United
States (Sigal et al. 1998; Steere et al.
1998). Both vaccines based on recom-
binant OspA and showed an efficacy
of 49-68% during the first year and 76-
92% during the second year after three-
stage vaccination on days 0, 30 and
360. CDC licensed in United States an
OspA vaccine for humans in Decem-
ber 1998. Unfortunately OspA vacci-
nes, because of the variability of OspA
in local B. burgdorferi sensu lato strains,
hardly are of any use in Europe.
2.9. Neurootological manifestations
of Lyme borreliosis
Facial nerve paralysis
Acute peripheral FP was first desc-
ribed in 1821 by Sir Charles Bell, who
defined the motor function of the se-
venth cranial nerve (Bell 1821). The
reported incidence of FP varies bet-
ween 11.5 and 40 annual cases per
100 000 of the population (Melotte
1961; Gregg 1961; Lagerholm et al.
1971; Hauser et al. 1971; Mair et al.
1974; Adour et al. 1978; Peitersen
1982; Katusic et al. 1986; Yanagihara
1988). The annual incidence of FP in
childhood is less than half of the cor-
responding incidence of FP in adults
(Adour et al. 1978; Peitersen 1982;
Katusic et al. 1986; Christen et al.
1993). In up to 75% of the cases the
etiology has remained obscure, and
the symptom has been called Bell’s
palsy (Adour 1982).
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Several factors have been suggested
for the etiology of FP, including ge-
netic, metabolic, autoimmune, vas-
cular, entrapment and infectious cau-
ses (Bauer et al. 1996). Diabetes mel-
litus and pregnancy are known pre-
disposing factors for FP (Adour et al.
1974; Hilsinger et al. 1975; Adour
1977). During the last two decades
viral infections, especially the herpes
simplex virus, have gained popula-
rity among investigators as a poten-
tial cause of FP (Barringer et al. 1973;
Adour et al. 1980; Morgan et al. 1992;
Murakami et al. 1996; Adour et al.
1996). Thus far the evidence impli-
cating HSV as a cause of FP is still
incomplete. However, based on em-
pirical evidence, acyclovir has been
proposed for the treatment of FP
(Adour et al. 1996). FP caused by the
Varicella zoster virus forms its own
entity.
Some bacterial diseases, including
spirochetal infections like syphilis
(Verduijn et al. 1982) and relapsing
fever (Southern et al. 1969), are
known to to induce FP. B. burgdorferi
also belongs to the group of spiroche-
tes capable of inducing FP. In a stu-
dy of almost 1000 patients with LB,
FP occurred in 10% (Clark et al. 1998).
Cranial neuropathies develop in
about 60% of the patients in early
neuroborreliosis and in 45% of the
patients in late neuroborreliosis (Reik
1991). Up to 55% of pediatric patients
with neuroborreliosis can incur FP
(Christen et al. 1993). FP accounts for
70-80% of all cranial nerve neuropat-
hies in early LB (Reik 1991) and about
one-third of them in late LB (Acker-
mann et al. 1988).
LB, or serological evidence of it, has
been found in 6-20% of adult patients
with FP (Åsbrink et al. 1985; Olsson et
al. 1988; Jonsson et al. 1990; Laurikai-
nen et al. 1990; Puhakka et al. 1992; Ro-
berg et al. 1991; Kuiper et al. 1992;
Hyden et al. 1993). The incidence of
LB is higher in pediatric patients than
in adults with FP. In studies on pedi-
atric FP, as many as two thirds of the
patients have had LB (Dotevall et al.
1994). In a German multicenter study,
LB was diagnosed in every third child
with FP and in every second child
during the warm season, and it was
the most frequently verifiable cause of
FP (Christen et al. 1993).
The spontaneous course of borrelial
FP and neuroborreliosis is predomi-
nantly favorable (Kruger et al. 1989;
Niemann et al. 1997). Although LB
is often a self-limiting infection, an-
timicrobial therapy is widely ac-
cepted and used to prevent rare la-
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ter complications. FP can be a mani-
festation of early LB without signs of
spirochetal dissemination, but it can
also be a manifestation of early or late
disseminated disease. Whether acu-
te disseminated B. burgdorferi infec-
tion should be treated differently
from localized infection is not known
(Dattwyler et al. 1997). Because of the
small number of controlled studies,
the optimal treatment of borrelial FP
also remains unknown. FP caused by
LB has been successfully treated with
intravenous penicillin (Jonsson et al.
1987; Olsson et al. 1988; Engervall et
al. 1995; Kindstrand 1995; Christen
1996), intravenous cephalosporins
(Pfister et al. 1989; Christen 1996) and
peroral tetracyclines (Dattwyler et al.
1997).
Sudden sensorineural hearing loss
SHL is a loss or impairment of hea-
ring that develops during a period
not exceeding a few hours or it is
present on awakening. The annual
incidence of SHL increases with ad-
vancing age and is reported to be
between 5 and 20 cases per 100 000
of the population. (Byl 1984)
Since the first published group of
patients with “idiopathic“ SHL in
1944 (De Kleyn 1944), it has been
shown that this disorder has nume-
rous possible causes, including infec-
tious, traumatic, neoplastic, im-
munologic, toxic, circulatory, neuro-
logic and metabolic factors (Hughes
et al. 1996).
Publications concerning the relation-
ship between LB and SHL are few. The
eighth cranial nerve or the vestibulo-
cochlear nerve is involved in less than
5% of cranial neuropathies in patients
with LB. LB seems to affect the
cochlear part of the nerve more often
(Reik 1992), but the vestibular part can
also be affected (Hanner et al. 1988).
There are some reports of SHL in pati-
ents with both early and late LB (Mo-
kry et al. 1990; Heininger et al. 1990;
Quinn et al. 1997; Zajkowska et al.
1998). In patients with ACA brainstem
response audiometry (BRA) has
shown abnormalities indicating the
involvement of central auditory path-
ways in chronic LB (Sandström et al.
1989). Serological evidence of LB has
been reported in about one-fifth of
patients with SHL (Hanner et al. 1989;
Hanner 1995). Patients with a favorab-
le effect from antimicrobial therapy on
long-lasting LB-related hearing deficit
have occasionally been reported (Les-
ser et al. 1990; Goldfarb et al. 1994;
Quinn et al. 1997; Zajkowska et al.
1998).
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Vertigo
Vertigo, dizziness and different types
of dysequilibrium are common clini-
cal problems. Although, in the me-
dical literature, the term vertigo is
used to include a hallucination of
turning or other motion separating
it from dizziness and other forms of
dysequilibrium, in this study it is
used to describe all forms of a sub-
jective perception of imbalance. The
etiology of vertigo is multifaceted
and includes various systemic dise-
ases, disorders of the CNS and more
specific disturbances in the equilib-
ratory apparatus ( vestibule, semicir-
cular canals, vestibulocochlear ner-
ve, vestibular nuclei in the brainstem
and their temporal lobe connections
and eyes). In neurootological clinics
the most common diseases involving
vertigo are Menière´s disease, benign
positional vertigo, vestibular
schwannoma, vestibular neuritis,
traumatic vertigo, sudden deafness
with vertigo, inflammatory diseases,
perilymphatic fistula, ototoxicity,
benign recurrent vertigo, benign pa-
roxysmal vertigo of childhood, inner
ear autoimmune disease, CNS tu-
mors, brainstem ischaemia, neuro-
vascular compression syndrome and
epilepsy (Kentala 1996).
The literature on vertigo in relation
to LB is sparse and limited to a few
papers. Rosenhall et al. (Rosenhall et
al. 1988) demonstrated serological
evidence of LB in 10 of 73 (14%) pa-
tients with vertigo. Ishizaki et al. (Is-
hizaki et al. 1993) showed positive
levels of antibodies against B. burg-
dorferi in 12 of 350 (3.4%) patients.
Riechelman et al. (Riechelmann et al.
1990) demonstrated that 8 of 45 (17%)
patients with vertigo had positive
levels of antibodies against B. burg-
dorferi, but they found the same rate
of seropositivity in the control group.
On the other hand, vertigo is not an
uncommon symptom among pati-
ents with disseminated LB. In series
of patients with LB the prevalence of
vertigo has varied between 8% and
26% (Krejcova et al. 1988; Moscatel-
lo et al. 1991; Wahlberg et al. 1993).
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3. AIMS OF THE PRESENT
STUDY
The aim of the present study was to
evaluate the prevalence and clinical
picture of LB among patients from
southern Finland presenting with
neurootological symptoms. These
symptoms included acute peripheral
FP, SHL and vertigo. In addition, the
endemicity rate of LB was studied in
the main patient enrollment area.
The specific aims of the study were
1. to determine prospectively the
prevalence of FP caused by LB in
southern Finland and to study the
characteristics of LB-related FP com-
pared with FP unrelated to LB (I);
2. to study prospectively LB as the
cause of pediatric FP and, in additi-
on, to evaluate retrospectively the
long-term prognosis of untreated FP
caused by LB (II);
3. to study prospectively the preva-
lence of LB in patients with SHL and
vertigo with special emphasis on
signs and symptoms possibly predic-
ting the occurrence of LB (III-IV) and
4. to estimate the density of I. ricinus
in recreational areas in Helsinki and
to assess the prevalence of B. burg-
dorferi in these ticks. Three different
methods (DFM, cultivation and PCR)
used in the detection of borreliae in
ticks were compared.
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4. PATIENTS AND MATERIALS
The patients for the present study
were examined in the Department of
Otorhinolaryngology (study I-IV) or
in the Departments of Paediatrics
and Otorhinolaryngology (study II)
of the Helsinki University Central
Hospital.
4.1. Study I
For study I, 503 patients with acute
idiopathic lower motoneuron FP
were consecutively examined from
1993 through 1994. On admission,
the patients filled out a questionnai-
re concerning symptoms and signs
related to LB, and their sera were
screened for antibodies to B. burgdor-
feri by ELISA. For patients with a cli-
nical suspicion of LB or positive
levels of antibodies against B. burg-
dorferi, CSF and sera were analyzed
by PCR for DNA of B. burgdorferi. The
CSF specimens also were subjected
to routine chemical (protein and glu-
cose concentration) and cytological
(leucocyte count) analyses to estima-
te the degree of CNS inflammation.
The outcome of the FP was evalua-
ted by another questionnaire (mean
follow-up of 3 years) concerning re-
covery from FP and possible residual
symptoms.
4.2. Study II
Study II consisted of an evaluation of
49 consecutively examined children
(<17 years) with 50 episodes of FP from
April 1994 through September 1996.
The patients were carefully intervie-
wed with special emphasis on tick bi-
tes and signs or symptoms of LB in
their history, and their sera and CSF
were analyzed for B. burgdorferi DNA
and for antibodies against B. burgdor-
feri. Other laboratory tests included
leucocyte count, sedimentation rate, C-
reactive protein concentration in the
blood and routine chemical and cyto-
logical analyses of the CSF. The CSF
was also incubated in BSK-II medium
for the cultivation of B. burgdorferi.
Study II included a retrospective ana-
lysis of 43 children who had had FP
an average of 5 years earlier. These
patients had not been previously exa-
mined for LB, nor had they been trea-
ted for FP with antimicrobial agents.
On admission the patients completed
a questionnaire, with special empha-
sis on possible signs and symptoms of
chronic LB. The examination of the
children included an otoneurological
evaluation, screening for B. burgdorfe-
ri DNA and antibodies against B. burg-
dorferi in their serum and an
assessment of leucocyte count, sedi-
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mentation rate and C-reactive protein
concentration in their blood. B. burg-
dorferi DNA, antibodies against B.
burgdorferi and routine chemical and
cytological parameters were also ana-
lyzed from the CSF. Sera and CSF were
also incubated in BSK-II for the culti-
vation of B. burgdorferi.
4.3. Study III
In study III, 168 patients with idio-
pathic SHL during 1993-1994 were
consecutively and prospectively stu-
died for antibodies against B. burg-
dorferi. On their admission signs or
symptoms possibly related to LB
were given a special attention. For
the seropositive patients, sera and
CSF were analyzed for B. burgdorferi
DNA, for antibodies against B. burg-
dorferi, and for signs of inflammati-
on. The patients were given an
audiological evaluation that inclu-
ded pure tone audiometry with air
and bone conduction thresholds and
brainstem auditory responses (Nico-
let Spirit). The audiological outcome
data included the pure tone average
(PTA), the PTA recovery percent and
the PTA improvement percent. In
case of any suspicion of retrocochlear
pathology, posterior fossa, including
the internal acoustic meatus, was
scanned by magnetic resonance ima-
ging (MRI) or computed tomo-
graphy (CT).
4.4. Study IV
In study IV 2055 consecutive vertigo
patients who entered to the depart-
ment from 1993 through 1994 were
examined for the prevalence of LB.
The diagnoses of these patients in-
cluded a wide range of neurootolo-
gical, neurological and vascular
causes of vertigo. The patients were
interviewed with special attention
being paid to possible signs and
symptoms related to LB. The sera of
patients were screened for antibodies
against B. burgdorferi, and those with
positive levels of antibodies were
further analyzed by Western immu-
noblot and for B. burgdorferi DNA.
The CSF specimens of the seroposi-
tive patients were analyzed for B.
burgdorferi DNA and antibodies
against B. burgdorferi. The neurooto-
logical tests included the evaluation
of saccades, pursuit eye movements,
posturography and the caloric test.
The audiological evaluation inclu-
ded pure tone audiometry and BRA.
4.5. Study V
For study V, 726 I. ricinus ticks were
collected by dragging a 1m2 cloth
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through the vegetation of five recrea-
tional areas in Helsinki. The density
of ticks in the areas was estimated. The
ticks were processed further by open-
ing their shield and removing the mid-
gut. So that the prevalence of B.
burgdorferi could be determined and
the methods used for the detection of
B. burgdorferi in the ticks could be com-
pared, the midgut was cut in three pie-
ces, one for DFM, one for PCR analysis
and one for cultivation.
.
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5. METHODS
The methods are presented in detail
in original publications. The outlines
are as follows:
5.1. Enzyme linked immunosorbent
assay
IgM and IgG antibodies against B.
burgdorferi were measured by a com-
mercial flagellin-based ELISA kit
(Dako, Glostrup, Denmark) modified
by using titration of the antibodies as
described earlier (Seppälä et al. 1994).
Sera were diluted serially in three-fold
steps for the test and applied to the pla-
tes for overnight incubation. The
bound antibodies were detected by
biotin-labeled goat anti-human IgM
and IgG (Zymed, Los Angeles, CA,
USA). An end point titer was obtained
at an optical density level determined
by a cut-off control provided by the kit.
The titer limit for a positive IgG anti-
body level was 500, and for a positive
IgM level it was 2500. This cut-off cont-
rol material conformed with the level
of the mean +3 standard deviations
(SD) of the reference population living
in central Finland (Seppälä et al. 1994).
In Denmark and Sweden 98% of the
population have antibody levels be-
low this standard (Hansen et al. 1988).
The modifications to the commercial
ELISA kit were made in order to al-
low measurement of serum and CSF
antibodies in the same linear titration
scale, thereby allowing the calculati-
on of intrathecal antibody production
in combination with immunoglobulin
concentration data.
For the CSF the cut-off limits for both
the IgM and IgG antibodies were 3.0
in the same scale as applied to the
serum analysis. The IgG antibody ti-
ter in the CSF was divided by the to-
tal IgG concentration in the CSF. A
corresponding ratio was also calcu-
lated for the serum. If the calculated
ratio of the CSF was more than two-
fold higher than the ratio of the se-
rum, IgG antibodies to B. burgdorferi
in the CSF were considered to be int-
rathecally synthesized.
5.2. Western blotting
In study IV the sera from patients
with positive levels of antibodies
against B. burgdorferi were further
analyzed for IgG1 antibodies by Wes-
tern immunoblot using Finnish B.
afzelii strain KS1 as the antigen sour-
ce. The immunoblotting was perfor-
med as described by Seppälä et al.
(Seppälä et al. 1994). The sample was
considered positive when at least
four bands, out of those most regu-
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larly found in Finnish patients with
LB, were observed. These bands rep-
resented proteins with molecular
masses of 17, 19, 21, 30, 41, 48, 52 and
83 kDa.
5.3. Treponema pallidum antibodies
In an attempt to rule out syphilis as
a source of false positive serological
results, in studies I, III and IV, sera
were examined for T. pallidum anti-
bodies by a commercial hemaggluti-
nation assay (Porton Cambridge,
Newmarket, UK).
5.4. Polymerase chain reaction
PCR analyses were performed in all
the studies (I-V). The method for
DNA extraction and primers used in
the PCR assay for ticks in study V
differed from those used in clinical
studies I-IV.
In studies I-IV, the serum or CSF spe-
cimens were first treated with SDS,
and then DNA was extracted from
them with phenol chloroform, pre-
cipitated with ethanol, and finally
dissolved with water.
In study V, DNA was extracted from
the tick midgut by InstaGene DNA
extraction matrix (Bio-Rad Laborato-
ries, Hercules, CA, USA) according to
the instructions of the manufacturer.
In studies I-IV the target of the PCR
amplification was a segment of the
gene encoding the 41-kDa flagellin
of B. burgdorferi. The primers were
modifications (He et al. 1994) from
those described by Picken et al.
(Picken 1992). Oligonucleotides were
synthesized by an automatic DNA
synthesizer (Model 391 PCR- Mate
DNA Synthesizer; Applied Biosys-
tems, Foster City, CA, USA) based on
phosphoamidite chemistry. The PCR
reaction consisted of 40 cycles carried
out in a thermal cycler (HB-TR1,
Hybaid Ltd., Middlesex, UK). After
amplification, the reaction mixture
was run in an agarose gel stained
with ethidium bromide, and the PCR
products were visualized and pho-
tographed under ultraviolet light.
In study V a nested PCR test based
on the flagellin gene was used to de-
monstrate the presence of B. burgdor-
feri DNA in the tick midgut. Primers
BBSCH31 and BBSCH42 were used
in the first PCR that consisted of 25
cycles. Primers FL59 and FL7 were
used in the second PCR with 35
cycles (Schmidt et al. 1996). The PCR
product was visualized as already
described.
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The spirochetes grown from the ticks
were identified to the species level
by the PCR test based on amplifica-
tion of the 16S rRNA gene (Marconi
et al. 1992). The extracted DNA was
amplified with four sets of primers
specific for B. burgdorferi sensu lato
(LD primers), B. burgdorferi sensu
stricto (BB primers), B. afzelii (VS461
primers), and B. garinii (BG primers).
For the LD primers, 40 cycles of de-
naturation at 94°C for 1 minute, an-
nealing at 47°C for 30 seconds, and
extension at 72°C for 1.5 minute were
carried out. For the other primers, the
PCR procedure was the same, except
that the annealing was performed at
42°C. The resulting PCR products
were visualized by agarose gel
electrophoresis.
The samples giving ambiguous re-
sults in the PCR reactions specific for
B. afzelii and B. garinii were further
analyzed by PCR-based sequencing
of the flagellin gene. A 277 bp pro-
duct was obtained by using primers
FL7 (biotinylated) and FL59. The bio-
tinylated PCR products were rende-
red single stranded by streptavidin-
coated Dynabeads according to the
instructions of the manufacturer (Dy-
nabeads M-280 streptavidin; Dynal
AS, Oslo, Norway). Manual sequen-
cing was performed using Sanger’s
dideoxynucleotide chain termination
method and Sequenase 2.0 (United
States Biochemical Corp., Cleveland,
OH, USA) (Soini et al. 1994). The ob-
tained sequences were compared
with the flagellin gene sequences of
the type strains of B. afzelii Bo23 and
B. garinii 387.
Rigorous measures were undertaken
to avoid carry-over contamination
and contamination caused by amp-
licon. Pre- and post-PCR stages of the
process were carried out in physical-
ly separate rooms and by separate
technicians. Each PCR run included
a positive control containing DNA
extracted from reference strain B31
of B. burgdorferi sensu stricto (ATCC
35210). Furthermore, every fifth or
sixth tube of each run was used as a
negative control and subjected to all
sample treatment procedures.
5.5. Audiological evaluation
The audiological tests in studies III
and IV included pure tone audiomet-
ry recorded at frequencies of 0.125,
0.250, 0.5, 1, 2, 4 and 8 kHz, inclu-
ding the assessment of air and bone
conduction thresholds for both ears.
A Nicolet compact auditory electro-
diagnostic system (Nicolet Spirit, Ni-
colet Instrument Corporation,
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Madison, Wisconsin, USA) was used
for measuring the BRA.
5.6. Otoneurological tests (study IV)
The otoneurological tests included
the evaluation of saccades, pursuit
eye movements, posturography and
the caloric tests.
5.7. Criteria for the diagnosis of LB
Special emphasis was placed on the
critical evaluation of the diagnosis of
LB. The following criteria were used
for the diagnosis of LB:
Study I: in addition to seropositivity
to B. burgdorferi, the presence of one
or more of the following findings
were required: 1) presence or histo-
ry of untreated EM, 2) a positive le-
vel of antibodies to B. burgdorferi in
CSF, 3) a positive PCR test and 4) CSF
pleocytosis in children.
Study II: one or more of the following
findings were required: 1) positive
levels of serum or CSF antibodies to
B. burgdorferi, 2) presence or history
of untreated EM and 3) a positive
PCR test.
Study III: in addition to seropositivi-
ty to B. burgdorferi, at least one of the
following findings were required: 1)
history of EM or 2) a positive PCR
test.
Study IV: in addition to positive se-
rum levels of antibodies to B. burg-
dorferi, the presence of one or more
of the following findings were requi-
red: 1) history of untreated EM, 2) a
positive PCR test and 3) a positive
serum immunoblot.
5.8. Tick preparation, dark field
microscopy and cultivation of
B. burgdorferi (V)
The midguts of the ticks were remo-
ved under a stereo microscope and
placed in a drop of BSK-II medium
using small sterile forceps, a dispos-
able 28 G needle as a scalpel, and ste-
rile insect preparation needles.
A part of the tick midgut was placed
on a microscope glass in a drop of
BSK-II medium, and the number of
spirochetes in the sample was esti-
mated by DFM (Leitz, Laborlux D,
Nürnberg, Germany) by examining
100 fields with a magnification of
400x. Typical movement, morpholo-
gy and size were used as the identi-
fication criteria for borrelia. Another
part of the tick midgut was inocula-
ted immediately after the preparati-
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on into tubes containing BSK-II me-
dium supplemented with rifampin
(final concentration 100 mg/ml) and
phosphomycin (final concentration
50 mg/ml) and incubated at 30°C for
8 weeks or until growth was de-
tected. The growth media were exa-
mined by DFM every other week. If
growth appeared, the cultures were
passaged into new tubes containing
BSK-II medium without antibiotics.
5.9. Statistical methods
In study I and III, the correlations
between symptoms and signs in dif-
ferent subgroups of patients were
estimated with the chi-square test or
with an analysis of variance. Then
potential risk factors for poor out-
come and signs or symptoms possib-
ly explaining the occurrence of LB
were incorporated into logistic reg-
ression analyses. In study II, the
numbers of children and the preva-
lence of different signs and symp-
toms possibly explaining the
occurrence of LB were estimated
with the Mann-Whitney U-test and
Fisher´s exact test. In study V, the chi-
square test was used to test the asso-
ciation of borrelia prevalence in ticks
with factors possibly influencing the
infestation rate of the ticks. Interac-
tions between these factors and the
putative confounding effect caused
by the viability of ticks was tested
with log-linear modeling. The inde-
pendence of the occurrence of B. ga-
rinii and B. afzelii in ticks was tested
with Fisher´s exact test. The agree-
ment of the three methods used for
the detection of B. burgdorferi in ticks
was studied with kappa statistics,
and the statistical significance of the
disagreement was obtained with Mc-
Nemars´ chi-square test. These sta-
tistical data were obtained by the use
of Statistics 4.0 (Analytical Software)
and Statview 4.5 (Abacus Concepts
Inc.) programs.
5.10. Ethics
The study protocols (I-IV) were ap-
proved by the ethical committees of
the Department of Otorinolaryngo-
logy and the Department of Pediat-
rics (study I) of the University
Central Hospital of Helsinki.
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6. RESULTS
6.1. Lyme borreliosis in patients with
facial paralysis - a prospective
analysis of outcome and predic-
tive signs and symptoms (I)
Of the 503 patients enrolled to study I,
61 (12%) had positive levels of antibo-
dies to B. burgdorferi in their serum.
Eleven of these seropositive patients
had definite LB. Three LB patients had
history of EM. Positive levels of CSF
antibodies were present in eight LB pa-
tients and CSF pleocytosis was found
in five. The PCR test was positive in
none of the serum specimens and in
one of the CSF specimens.
FP caused by LB was significantly
more common during the summer
season (June-November) than the
winter season (December-May)
(p=0.039). Bilateral FP was rare in the
whole material (2.4%), but signifi-
cantly (p=0.0015) more common in
patients with definite LB (18%) than
in the rest of the patients (2%). Of the
signs and symptoms preceding or
coinciding with FP, fever (p=0.0018),
headache (p=0.012), pharyngalgia
(p=0.015), enlarged cervical lymph
nodes (p=0.0062) and arthralgia
(p=0.036) were more common in pa-
tients with definite LB. Swedish as a
native language was more common
among the patients with positive le-
vels of serum antibodies against B.
burgdorferi. In the logistic regression
analysis the best model to predict the
occurrence of LB included the pre-
sence of enlarged cervical lymph
nodes, the presence of arthralgia and
the onset of symptoms during the
summer season.
The outcome of facial paralysis (I)
The outcome of FP was evaluated by
a dedicated questionnaire (mean fol-
low-up 3 years) concerning recove-
ry from FP and possible residual
symptoms. Incomplete recovery
from FP was more common among
the patients with total paralysis
(p=0.002), patients with recurrent FP
(p=0.0005) and patients with arthral-
gia (p=0.005), vertigo (p=0.02) or
nausea (p=0.01) at the time of FP. In-
complete recovery was more fre-
quently reported by women than by
men (p=0.01). Hyperacusis was also
more common in the patients with
incomplete recovery, but the diffe-
rence was not significant (p=0.06). In
the logistic regression modeling the
factors in the model that best pre-
dicted incomplete recovery were the
presence of total FP, recurring FP and
hyperacusis.
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6.2. Pediatric facial paralysis caused
by Lyme borreliosis: a prospecti-
ve and retrospective analysis (II)
Of the 49 children with 50 episodes of
FP, 17 (35%) had LB. Eleven of the
children with LB had positive levels
of serum antibodies on admission, and
two children seroconverted during the
follow-up. Four children remained
seronegative, and the diagnosis of LB
in these patients was based on positi-
ve levels of CSF antibodies in one case,
a positive PCR result in one case and a
history of EM in two cases. Altogether
nine children had a history of untrea-
ted EM, and one child developed EM
four weeks after FP. Of the signs and
symptoms coinciding with or prece-
ding FP, headache (p<0.001) and
arthralgia (p<0.05) were more frequent
among the patients with LB. The pa-
tients with LB also recalled tick bites
more often than the other patients with
FP (p<0.01). The occurrence of FP
among patients with LB was more fre-
quent during the summer season
(p<0.001). The incidences of bilateral
FP and total paralysis were similar for
the patients with and those without
LB.
Abnormalities in the CSF analysis
were observed for 12 of the 41 pati-
ents and exclusively in patients with
LB. The intrathecal production of
antibodies to B. burgdorferi was pre-
sent in 8 children, and 11 children
had pleocytosis. The CSF protein
concentration was elevated in five
patients and the PCR analysis from
the CSF was positive in one patient.
The mean follow-up of the patients
was 28 months. The recovery was
complete (House-Brackmann grade
1) for 34 of the 49 (69%) patients. The
full recovery was more frequent for
patients with LB, but the difference
between the groups was not signifi-
cant. Most of the sequelae in both
groups were mild (House-Brack-
mann grade 2).
In the retrospective part of study II,
the children had no signs or findings
related to chronic LB. However, one
16-year-old girl had a positive serum
level of IgM antibodies against B.
burgdorferi coinciding with headache,
fatigue and arthralgia on admission.
During the follow-up of this patient,
a four-fold rise in IgM antibodies was
detected. Her history of three recent
camping trips to an area hyperende-
mic for LB in the Finnish southwes-
tern archipelago supports the
concept that she had an acute borre-
lia infection at the time of the inves-
tigation.
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6.3. Lyme borreliosis, an etiologic
factor of sensorineural hearing
loss? (III)
In this prospective study 20 of 165
(12%) patients with SHL had positive
levels of antibodies to B. burgdorferi,
and 4 of them fulfilled the criteria for
definite LB. Two of the patients with
definite LB had a history of untreated
EM, and two had a positive result in
the Borrelia-PCR analysis in the serum.
In the CSF analysis of the seropositive
patients none had intrathecal synthe-
sis of antibodies against B. burgdorferi,
and all of them had a negative result
in the Borrelia-PCR analysis.
The statistical analysis of audiological
recovery and the prevalence of tinni-
tus and vertigo in seronegative pati-
ents (n=145), seropositive (probable
LB) patients (n=16) and definite LB pa-
tients (n=4) revealed no significant dif-
ferences between these groups. No
significant differences were found,
when the clinical data of the patients
in different groups was cross-tabula-
ted. Thus no specific signs or symp-
toms were found to predict the
occurrence of LB in patients with SHL.
The seasonal distribution of SHL was
even in all the subgroups, with a slight
accumulation of cases in early spring
and late autumn.
The clinical data of all the patients
were cross-tabulated, and the signi-
ficance of single symptoms and signs
as explanatory factors for recovery
was tested with the chi-squaretest.
Patients with a fair to poor recovery
(Mattox et al. 1977) were more fre-
quently older than 40 years (p=0.013)
and had a high frequency or flat-type
hearing loss more frequently
(p=0.0015), when compared with
those with good recovery. In the lo-
gistic regression modeling the factors
in the best model explaining excel-
lent to good recovery included
young age, mid-frequency hearing
loss and positive levels of antibodies
against B. burgdorferi.
6.4. Lyme borreliosis as a cause of
vertigo (IV)
Of the 2055 prospectively screened
patients with vertigo, 41 (2%) had
positive levels of antibodies against
B. burgdorferi and 6 of them fulfilled
the diagnostic criteria for LB. The
incidence of seropositivity to B. burg-
dorferi in patients with vertigo did
not differ from the corresponding in-
cidence of the general Finnish popu-
lation. Of the patients with LB, three
had a history of untreated EM, and
the seropositivity was confirmed
with immunoblotting for all but one
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of these patients. The serum Borre-
lia-PCR analysis was positive in two
cases. The Borrelia-PCR analysis of
CSF was negative in all cases. The
CSF specimens of the 16 seropositi-
ve patients were analyzed for protein
concentration and cell counts and
found to be normal.
The vertigo of patients with LB was
rotational in six patients and, positio-
nal in one; in addition one patient suf-
fered from drop attacks of the
Tumarkin type. Two patients showed
evidence of CNS affection in the oto-
neurological tests. Five patients had
symptoms resembling Menière´s dise-
ase. Seven of the eight patients recei-
ved antimicrobial therapy, and the
response was estimated as good (ver-
tigo disappeared during medication
and patient had no symptoms at the
end of the follow-up) in three cases and
moderate (a considerably decreased
vertigo after the medication) in four
cases. After the treatment the mean
follow-up of the patients was 30
months.
6.5. Prevalence of Borrelia burgdorfe-
ri in Ixodes ricinus ticks in urban
recreational areas of Helsinki (V)
Altogether 726 I. ricinus ticks were
collected from five popular recreati-
onal areas in Helsinki to estimate the
density of ticks and to assess the in-
festation rate of ticks with B. burgdor-
feri. The estimated number of annual
visitors to these areas is 1.4 million
(Helsinki 1997). The tick densities
varied from 1 to 36 ticks for every 100
meters of flagging with a 1m2 piece
of fabric. All the tick populations
were infected with B. burgdorferi, and
the infestation rate varied from 19%
to 55%. The chi-square analysis indi-
cated that the infection rate was as-
sociated with the area from which the
ticks were collected (p<0.001), but
not with the developmental stage
(p=0.06) or viability of the ticks
(p=0.19). A log-linear analysis, taking
into account the possible confoun-
ding effects of a uneven distribution
of developmental stage and the via-
bility of the ticks in different areas,
confirmed the significant difference
between the infestation rates of the
different areas.
Altogether 234 ticks were Borrelia-
positive in the cultivation (n=144),
DFM (n=193) or PCR (n=135). Of the
142 cultivated and typable B. burg-
dorferi strains, 100 (70%) belonged to
the subspecies B. afzelii and 37 (26%)
to the subspecies B. garinii. Five
strains were untypable; yet no B.
burgdorferi sensu stricto strains were
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found. Mixed infection with both B.
afzelii and B. garinii was rare and
found in two ticks only.
The DFM gave more positive results
than either the culture (p<0.001) or
PCR analysis (p<0.001). The compa-
rison of the three different methods
with kappa statistics showed a fairly
good agreement between them (kap-
pa value between 0.53 and 0.59 in all
the comparisons).
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7. DISCUSSION
The present study evaluated the oc-
currence of LB in patients with neu-
rootological complaints in an area
endemic for LB. The results show the
importance of LB in the diagnostic
work-up of an otorhinolaryngologist.
LB is a frequent diagnosable cause of
FP in adult patients (I) and it is espe-
cially frequent in pediatric patients
(II). It was also shown that vestibulo-
cochlear dysfunctions, i.e. SHL (III)
and vertigo (IV) can be caused by LB.
The endemicity of the patient enroll-
ment area was confirmed by de-
monstrating an abundance of I. rici-
nus ticks and their high infestation
rate with B. burgdorferi in the area
where most of the patients live. (V).
7.1. Laboratory diagnosis of Lyme
borreliosis
Findings in cerebrospinal fluid
CSF abnormalities are frequently
found in patients with LB. Lympho-
cytic pleocytosis and an elevated to-
tal protein concentration is a charac-
teristic finding in the CSF of patients
with Bannwarth´s syndrome. LB-as-
sociated peripheral neuropathies in-
cluding cranial neuropathies are of-
ten, but not always, accompanied by
lymphocytic meningitis (Halperin
1998). The analysis of CSF has been
emphasized for selected patients
with cranial neuropathy to verify
borrelial etiology (Kindstrand 1995).
In the present study most of the pa-
tients with FP caused by LB (81% and
70% in studies I and II, respectively)
had abnormalities in their CSF, whe-
reas none of the patients with LB-re-
lated SHL or vertigo had any.
These CSF abnormalities seemed to
be age-dependent. In study I (mean
age of the patients 28 years), 45% of
the patients had pleocytosis, and the
same proportion also had increased
protein concentration in their CSF. In
study II (mean age of the patients 8.4
years) increased protein concentrati-
on was observed in 29% of the pati-
ents, whereas pleocytosis was pre-
sent in 65% of them.
The findings show the importance of
CSF analysis in the search of etiolo-
gy of FP in areas endemic for LB.
Patients with SHL and vertigo did
not show CSF abnormalities, probab-
ly because of the long time that had
passed since the initial infection. The
results do not encourage routine CSF
analysis of patients with these dise-
ase manifestations.
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Culture
The gold standard for the diagnosis
of LB is cultivation of the pathogen
from body fluids or tissues. This stu-
dy showed, again, that the isolation
of B. burgdorferi from clinical speci-
mens is difficult. The culture was
negative in all the specimens studied.
This low yield of culture is in accor-
dance with the experience of others.
The CSF from patients with neuro-
logical manifestations of LB has been
positive in only 7-10% of patients
(Karlsson et al. 1990; Wilske et al.
1993). A positive culture from the
CSF is more frequent in manifesta-
tions of short duration (Karlsson et
al. 1990). The clinical type of speci-
men most frequently positive (up to
70%) in cultures is the biopsy from
EM (Wilske et al. 1993). However, in
clinical practice the diagnosis of EM
is straightforward without cultivati-
on and other laboratory tests.
The cultivation of B. burgdorferi was
first accomplished from I. scapularis
ticks by Burgdorfer et al. in 1981
(Burgdorfer et al. 1982), and it has
later been successfully used in stu-
dies on the prevalence of B. burgdor-
feri in ticks (Ackermann et al. 1984;
Junttila et al. 1994; Strle et al. 1995;
Humair et al. 1995; Solari Basano et
al. 1996). The present study also sho-
wed that B. burgdorferi can be culti-
vated much more effectively from
the midguts of the ticks than from
clinical specimens (V).Thus the neg-
ligible yield of cultures from clinical
specimens could not be, at least so-
lely, attributed to an inadequate cul-
ture procedure because the same pro-
cedure was used for all the specimen
types.
There are at least two plausible exp-
lanations for the low yield of cultu-
res of B. burgdorferi from clinical spe-
cimens. First, B. burgdorferi may oc-
cur only temporarily and in low
numbers in body fluids and tissues
during the course of infection (Pach-
ner 1998). The problem of a small
bacterial number can be solved only
by introducing large volumes of a
specimen to the culture medium.
Such a procedure is not, however,
always possible because of the low
amount of specimen available. Se-
cond, host defense factors may im-
pair the viability of B. burgdorferi not
only in vivo but also later in vitro.
The fact that the pathogen can be re-
latively easily isolated from ticks
may be due to both of these reasons.
The number of B. burgdorferi in ticks
is rather large – the organism can ea-
sily be seen by light microscopy in
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tick midgut preparations. It is also
possible that the primitive defense
mechanisms of ticks do not impair
the viability of B. burgdorferi to the
same extent as mammalian immune
defense does.
A recent study showed that, by opti-
mizing growth conditions, it may be
possible to increase the yield of cul-
tivation even for specimens from
patients with chronic LB (Phillips et
al. 1998). For the present, however,
cultivation remains an impractical,
but promising method for the clini-
cal diagnosis of LB. For scientific
purposes, the patients with culture-
proven LB, however, are extremely
valuable.
Antibody measurement
ELISA is the most suitable method
for the screening of serum and CSF
antibodies against B. burgdorferi in
patients with symptoms suggestive
of LB (Golightly 1993). The assess-
ment of antibodies has its limitations,
however. Some of the limitations of
serologically testing LB are true for
all serologic tests, and some are spe-
cific to this infection. In general the
antibody response takes time to de-
velop, and in the early course of LB
a considerable proportion of the pa-
tients remain seronegative (Strle et al.
1996). Second, the antibody respon-
se may persist for a long time (Fah-
rer et al. 1998). Thus positive levels
of antibodies may reflect both old
immunity and active infection.
Third, antibodies reactive with B.
burgdorferi antigens can be elicited by
other infectious agents because of
cross-reactive antigenic molecules or
epitopes (Seppälä et al. 1994; Burkot
et al. 1997). Fourth, many illnesses
can induce polyclonal B-cell expan-
sion (e.g., infectious mononucleosis
and subacute bacterial endocarditis),
which can lead to false positive reac-
tions in antibody determinations
(Kaell et al. 1990). Fifth, individual
antibodies are produced against mo-
lecular epitopes, not against specific
bacteria, and cross-reactivity occurs
between epitopes resembling each
other. Sixth, the complexity of B.
burgdorferi offers various approaches
to antigen preparation, ranging from
the use of sonicated whole cell lysa-
tes to highly purified or recombinant
antigens (Magnarelli et al. 1996; Hau-
ser et al. 1997). Usually however, the-
se highly purified singular antigens
improve the specificity of the assay
at the cost of sensitivity (Oksi et al.
1995). For the moment, the choice of
the best antigen(s) for ELISA remains
unresolved.
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There has been an avid discussion on
seronegative LB. This is a natural sta-
te in the early phases of the disease,
but it can definitely occur also at la-
ter stages of LB (Dattwyler et al. 1988;
Guy et al. 1989; Oksi 1996). One rea-
son for the seronegativity may be
early antimicrobial treatment that
can permanently abrogate the anti-
body response without completely
eliminating the organism (Dattwyler
et al. 1988). It is also possible that the
immune system of some persons
does not mount a response to borre-
lial antigens. The mechanisms be-
hind this unresponsiveness remain to
be clarified.
Although most of the patients with
extracutaneous LB almost always
have positive levels of serum antibo-
dies to B. burgdorferi, in the early
course of the disease some patients
may have positive levels of CSF an-
tibodies only (Tugwell et al. 1997).
This phenomenon was also seen in
the present study. One patient (stu-
dy I) was seronegative, but proved
to have positive levels of CSF anti-
bodies to B. burgdorferi.
In this study, the intrathecal produc-
tion of antibodies to B. burgdorferi
was taken as one of the inclusion cri-
teria for definite LB. This criterion
was met in 73% of the LB patients in
study I (mean age of the patients 28
years) and 47% of the LB patients in
study II (mean age of the patients 8.4
years). Although our findings show
that the lack of CSF antibodies does
not exclude LB, the analysis of CSF
antibodies is important in the diag-
nosis of FP in areas endemic for LB.
In contrast to FP, no intrathecal anti-
body production could be found for
the patients with SHL and vertigo.
The cut-off titers of the flagellin-
based ELISA used in this study con-
form with the antibody level of a
mean +3 SD of the general populati-
on from nonendemic area in central
Finland. This definition means that
1.25% of the healthy normal popula-
tion provides a positive result in the
antibody measurement. According to
this definition, the patients with FP
(I) and SHL (III) had a high preva-
lence (12%) of seropositivity against
B. burgdorferi. This finding agrees
with the results of previous studies,
which have shown, that cranial ner-
ve dysfunctions, especially the affec-
tion of the facial nerve, are frequent
and well-documented manifesta-
tions of LB (Kindstrand 1995). In this
study, 2% of the patients with verti-
go (IV) had positive levels of antibo-
dies to B. burgdorferi, which accords
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with the seropositivity rate of the
general population. The study de-
monstrates the rarity of LB as the
cause of vertigo.
With the afore mentioned limitations
of serological screening taken into
account, the interpretation of positi-
ve test results must be made cau-
tiously. In the present study special
emphasis was put on the criteria of
the diagnosis of definite LB, which
was confirmed for 11 of 61 (18%), 4
of 20 (20%) and 8 of 41 (19%) seropo-
sitive patients with FP, SHL and ver-
tigo, respectively. However, the po-
sitive serological results in the pati-
ents not fulfilling the criteria used for
definite LB are not necessarily all fal-
se. It is probable that there are real
LB cases among these patients, and
better diagnostic tests are needed in
the future to reveal them.
Although the application of strict cri-
teria, while necessary to avoid vast
overdiagnosing of LB, may allow
some seropositive patients to be un-
derdiagnosed, it can be considered to
be a less serious problem than uncri-
tical overdiagnosing (Sigal 1996). On
the other hand, the analysis of only
one specimen from each patient ma-
kes it possible for some single pati-
ents with LB to be missed because of
the early phase of the disease. In cli-
nical practice, clinical and laborato-
ry follow-up of the patients with
symptoms that arouse suspicion of
LB must be underlined.
Is it necessary to screen patients with
neurootological symptoms for anti-
bodies to B. burgdorferi? If the utmost
importance of the history and clini-
cal evaluation of the patient in the
diagnosis of LB is kept in mind, the
present study shows that the scree-
ning of serum antibodies to B. burg-
dorferi is helpful in the differential
diagnosis of FP and SHL. However,
the screening of vertigo patients for
antibodies to B. burgdorferi, even in
areas endemic for LB, seems not to
be recommendable.
There is an obvious need for the furt-
her development of serological and
other laboratory methods for the
diagnosis of LB. The CDC in the Uni-
ted States recommends that positive
or borderline serological results be
confirmed with Western blotting
(Ledue et al. 1996). The reliability of
this two-test approach has been ques-
tioned (Tugwell et al. 1997). The use
of Western blotting in Europe is dif-
ficult because of the heterogeneity of
B. burgdorferi sensu lato. A recent eva-
luation based on a large panel of
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European patient sera suggests that
a method with sufficient sensitivity
can be obtained using the B. afzelii
strain Pko as a source of antigen
(Hauser et al. 1997; Hauser et al.
1999). Each laboratory using this
strain should confirm that their strain
expresses the diagnostically impor-
tant proteins. The problem of variab-
le protein expression can be solved
only by a centralized or commercial
production of the antigen preparati-
on for European Western blotting.
Polymerase chain reaction
PCR has opened a new era in the
diagnosis of infectious diseases, and
it is a promising method in the diag-
nosis of LB as well. While being sen-
sitive in the detection of spirochetal
DNA from the tick midgut, as also
shown in this study (V), the results
of PCR in the clinical diagnosis of LB
have varied (Schmidt 1997). In the
present study PCR was positive in
one serum (II) and two CSF (I and II)
samples from patients with FP and
two serum samples from both pati-
ents with SHL (III) and with vertigo
(IV). PCR testing can sometimes de-
tect B. burgdorferi DNA in CSF of pa-
tients with acute or chronic neuro-
borreliosis, but the sensitivity of the
current tests has generally been low
(Christen et al. 1995; Nocton et al.
1996; Issakainen et al. 1996). The low
yield of PCR from sera and CSF may
reflect technical limitations in the
performance of PCR, but more like-
ly it is caused by the minimal and
transient occurrence of borrelial
DNA in the CSF and blood during
the course of LB (Pachner 1998). In
diseases like LB, for which a minute
amount of pathogens causes the
symptoms, there is a need to capture
the pathogen specifically from a lar-
ge specimen volume in the small ali-
quot used for PCR. One way of achie-
ving this is to use an immunomag-
netic concentration of the pathogen
(Stark et al. 1996). Despite its limita-
tions, I advocate the use of PCR in
addition to clinical assessment and
other laboratory methods in the diag-
nosis of LB.
7.2. Lyme borreliosis in patients
with neurootological symptoms
Cranial neuropathies are well docu-
mented manifestations of LB. The
facial nerve is the most commonly
affected, followed by the nerves to
the extraocular muscles, the trigemi-
nal nerve and the vestibulocochlear
nerve (Reik 1991). The list of various
causes possibly responsible for the
dysfunction of the facial nerve is
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long. Recent results by Murakami et
al. (Murakami et al. 1996) suggest
that reactivation of Herpes simplex
virus infection is an important cause
of idiopathic FP. However, these re-
sults remain to be confirmed by ot-
her research groups. FP can be one
of several other concomitant symp-
toms in LB, but it can still be the sing-
le presenting symptom. In the latter
case LB-related FP is not easy to dis-
tinguish from Bell´s palsy. In the pre-
sent study (II), the features of the cli-
nical picture, signs and findings that
best explain the occurrence of LB in
patients with FP, were evaluated. The
risk for LB as the cause of FP was
highest in patients with enlarged cer-
vical lymph nodes, arthralgia and the
onset of the symptom during June-
November. None of these factors is
pathognomonic for LB, but in clini-
cal practice an awareness of these
risk factors may facilitate the diffe-
rential diagnosis.
Bilateral FP has been shown to be as-
sociated with LB, the reported preva-
lences ranging from 29% to 71% (Pfis-
ter et al. 1993). In the present study (I),
bilateral FP was present in a fifth of
the patients with definite LB, whereas
only 2% of the seronegative patients
had bilateral FP. However, in the stu-
dy on pediatric FP (II) bilateral FP was
equally common in patients with and
without LB (6%). In a series of Bell´s
palsy, bilateral involvement occurs in
less than 1% (Adour et al. 1978). In the
case of bilateral FP the clinician must
be aware not only of LB, but also of
other specific causes, as for example
the Guillan Barré syndrome, malig-
nant diseases and other infectious cau-
ses (Keane 1994).
The earlier information of the occur-
rence of LB in SHL and vertigo is
scarce. However, both of these ma-
nifestations have been described as
evolving in both early and late LB
(Pachner et al. 1989; Reik 1991). The
results of the present investigation
show that LB should be taken into
account as a causative factor of SHL.
In contrast, LB plays a marginal role
in the pathogenesis of vertigo.
T. pallidum, the causative agent of
syphilis, belongs to the same order
(Spirochaetales) as B. burgdorferi.
Syphilis is a well documented cause
of symptoms mimicking classic
Meniere´s disease (Pulec 1972). The-
re are many similarities in the clini-
cal course of syphilis and LB (Pach-
ner 1989). An interesting observati-
on in this study was that vertigo
caused by LB can mimic the symp-
toms of Menière´s disease.
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7.3. Outcome of patients with Lyme
borreliosis
The spontaneous course of neurolo-
gical symptoms of LB is relatively
well described in the literature from
the era before the discovery of B.
burgdorferi. These data include, how-
ever, limitations of retrospective ana-
lyses and must be interpreted with
caution. In the United States, 55 unt-
reated patients with EM were follo-
wed for several years, and 80% of
them developed arthritis or muscu-
losceletal pain, 9% experienced re-
current EM, 8% developed neurolo-
gical symptoms and 4% had cardiac
abnormalities (Steere et al. 1987).
Bannwarth´s syndrome, which inclu-
des painful meningoradiculitis, cra-
nial nerve affection - in most cases
FP - and lymphocytic pleocytosis in
CSF, has been a self-limiting mani-
festation in the majority of patients
(Pfister et al. 1993).
The present results strongly support
the favorable outcome of LB-related
FP. In study II, 43 children with a his-
tory of FP were retrospectively eva-
luated for the outcome of FP and for
symptoms or signs of late LB. In the
light of the concomitant prospective
study, there was a considerable rea-
son to suspect that up to one-third
of these children had their untreated
FP caused by LB. The outcome of FP
in these children was good, and no
signs or findings of late LB were
found in these children. However,
since the risks of adverse events due
to antimicrobial medication are rela-
tively low, patients with definite LB
should be treated with appropriate
antimicrobials.
7.4. Evaluation of the density of
ticks and their infestation rate
with B. burgdorferi
Knowledge of the epidemiology of
the vectors of LB and their infestati-
on rate is essential for understanding
the risk of LB in a local setting. The
present study (V) confirmed the en-
demicity of LB in the study area by
demonstrating not only the high den-
sity of I. ricinus ticks, but also the high
infestation rate of ticks by B. burgdor-
feri (average 32%).
With the exception of the most nort-
hern regions, the distribution area of
ixodid ticks covers all of Europe. The
density of ticks varies as a function of
geographic area (e.g., proper habitat,
density of host animals) and time (e.g.,
variation of humidity from year to
year) considerably (Gray et al. 1998).
In Europe the ticks have a bimodal
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seasonal activity with activity peaks in
early summer and early autumn. Usu-
ally, tick densities have been studied
in rural areas, although there is gro-
wing evidence of the occurrence of
ticks in urban settings (Steere 1994).
Our results confirm that even very
urban parks can serve as habitats for
I. ricinus ticks. Study V demonstrated
tick populations residing in abundan-
ce in the vicinity of the city center of
Helsinki, the most densely populated
area of Finland. Of special interest was
the finding, contrary to previous re-
ports, that dense populations of I. rici-
nus ticks can exist in an urban envi-
ronment not populated with large
mammals like the deer or elk. Our fin-
dings underline the necessity of inha-
bitants and local health care officials
to be aware of the risk of contracting
LB in city parks and other recreational
areas.
B. burgdorferi spirochetes have been
found in all the I. ricinus populations
examined in Europe (Hubalek et al.
1998). The present study (V) confirms
this finding. The published data on
the infestation rate of ticks vary con-
siderably according to the method
used for the detection of the spiroche-
te. Extensive comparative studies
between different detection methods
have not been available. The present
study (V) compared DFM, cultivati-
on and PCR as methods of detecting
B. burgdorferi in the midgut of I. rici-
nus ticks. The agreement between the
performance of the three methods
was fairly good. DFM provided a
positive result for some of the speci-
mens that remained negative both in
culture and in the PCR analysis. The-
se specimens generally contained
very low numbers of spirochetes, a
finding which suggests that DFM
may be more sensitive than the ot-
her two methods. The specificity of
DFM has been argued about, and the
present study could not rule out the
occurrence of an unknown organism
morphologically similar to B. burg-
dorferi in the ticks positive only with
DFM. However, in practice DFM is
the method of choice for routine
screening of tick infestation rates.
The three European isolates of B.
burgdorferi are associated with diffe-
rent late clinical manifestations (As-
sous et al. 1993; Canica et al. 1993).
In this context the finding that the I.
ricinus ticks found in Helsinki har-
bor B. afzelii and B. garinii only is of
clinical importance. The absence of
B.burgdorferi sensu stricto in the ticks
in Helsinki may explain the rarity of
frank arthritis in the patients with LB
in this study.
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8. CONCLUSIONS
1. LB is an important infectious cau-
se of FP (I) and especially in FP in
children (II) in southern Finland. It
is advisable to screen patients with
FP for antibodies to B. burgdorferi in
endemic areas like southern Finland.
In the diagnosis of LB, special atten-
tion must be paid to the history of
the patient and clinical signs and fin-
dings related to LB. Suspicion of LB
in a patient with FP is an indication
for the analysis of the CSF. Fever,
headache, pharyngalgia, enlarged
cervical lymph nodes and arthralgia
were more frequent in patients with
LB-related FP than in other FP patie-
nts. Suspicion of LB as the cause of
FP must be especially high during
late summer and autumn. Strict cri-
teria must be applied to the diagno-
sis of LB to avoid overdiagnosis.
2. SHL can be caused by LB (III). The
prevalence of antibodies to B. burgdor-
feri in patients with SHL was six-fold
higher than the corresponding preva-
lence in the general population. No
special signs or symptoms were found
to explain the occurrence of LB in the-
se patients. Serological screening for
antibodies to B. burgdorferi is recom-
mended in patients with SHL in areas
endemic for LB.
3. LB can, although rarely, present
with vertigo. Vertigo caused by LB
may mimic the symptoms of
Menière´s disease. The prevalence of
antibodies to B. burgdorferi in unse-
lected patients with vertigo was
equal to the corresponding prevalen-
ce in the general population. There-
fore, the routine screening for anti-
bodies against B. burgdorferi in pati-
ents with vertigo is not recommen-
dable.
4. Although the neurootological ma-
nifestations of LB seem to have a fa-
vorable outcome even without treat-
ment, patients with definite LB
should be treated with appropriate
antimicrobials.
5. The present study demonstrates
that I. ricinus ticks are abundant in
the vicinity of the city center of Hel-
sinki. In contrast to previous studies,
the occurrence of ticks was confir-
med in the absence of large mammals
like deer and elk. Of the three genos-
pecies of B. burgdorferi causing LB in
Europe, one, B. burgdorferi sensu
stricto, was absent in the ticks in Hel-
sinki. This finding may explain the
rarity of frank arthritis in the patie-
nts with LB in the present study. Al-
together 32% of the ticks in Helsinki
harbored the spirochete B. burgdorferi.
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This information from the popular
recreational areas of a densely popu-
lated metropolitan area should alert
the local health officials to inform the
population about the risk of contrac-
ting LB and about the need for pre-
ventive measures.
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9. SUMMARY
Lyme borreliosis, although clinically
known for more than a decade, is
scientifically a rather new disease. The
isolation of the causative agent of this
multifaceted syndrome in 1981 open-
ed an era of ever increasing intensive
scientific work. Neurootological
symptoms of Lyme borreliosis, espe-
cially the paralysis of facial nerve, have
played a central role in the clinical pic-
ture of Lyme borreliosis. The purpose
of the present study was to evaluate
Lyme borreliosis as the cause of verti-
go, sudden sensorineural hearing loss
and facial paralysis. Additionally, the
endemicity of Lyme borreliosis in our
study area was assessed by studying
the density of Ixodes ricinus ticks and
their infestation rate by Borrelia burg-
dorferi in city parks of Helsinki.
During a two year period, 503 con-
secutive patients with acute idiopat-
hic facial paralysis were prospective-
ly screened for antibodies to Borrelia
burgdorferi. In the same way we eva-
luated 49 children with facial para-
lysis, 165 patients with sudden sen-
sorineural hearing loss and 2055 pa-
tients with vertigo. Clinical symp-
toms and signs related to Lyme bor-
reliosis were evaluated.
Of the 503 patients with facial para-
lysis, 61 (12%) had positive levels of
serum antibodies against Borrelia
burgdorferi and, according to the cli-
nical criteria used for the diagnosis
of Lyme borreliosis, 11 of them had
Lyme borreliosis. Of the 49 children
with facial paralysis, 17 (35%) had
Lyme borreliosis, and of the 165 pa-
tients with sudden sensorineural
hearing loss, 20 (12%) had positive
levels of serum antibodies against
Borrelia burgdorferi, and according to
the clinical criteria 4 of them had
Lyme borreliosis. In patients with
vertigo Lyme borreliosis was rare;
41/2055 (2%) had positive levels of
antibodies against Borrelia burgdor-
feri, which did not differ from the
incidence of seropositivity among
the normal Finnish population. Ac-
cording to the clinical criteria eight
patients (0.4%) were diagnosed as
having Lyme borreliosis.
Altogether 726 Ixodes ricinus ticks
were evaluated from five recreatio-
nal parks in Helsinki. The density of
ticks varied from 1 to 36 per 100 m
along the tract on which the collecti-
on cloth was dragged. Ticks were
dissected and the midgut of the ticks
was analysed for the presence of Bor-
relia burgdorferi by dark-field micros-
copy, cultivation in the BSK-II me-
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dium and polymerase chain reacti-
on. The agreement between the three
methods for detection of Borrelia
burgdorferi was good. The rate of ticks
infected with Borrelia burgdorferi sen-
su lato varied from 19% to 55%, the
average being 32%. Borrelia afzelii was
the most predominant genospecies in
all the areas and no Borrelia burgdor-
feri sensu stricto isolates were de-
tected.
In summary, the present study shows
the importance of Lyme borreliosis in
the differential diagnosis of patients
with otoneurological complaints.
Lyme borreliosis is a common identi-
fiable cause of facial paralysis and sud-
den sensorineural hearing loss. As the
cause of vertigo Lyme borreliosis is
rare. In endemic areas, like major parts
of Finland, Lyme borreliosis must be
taken into account in the diagnostic
workup of an otorhinolaryngologist or
neurootologist.
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